NZ614658B2 - Antibody fc variants - Google Patents
Antibody fc variants Download PDFInfo
- Publication number
- NZ614658B2 NZ614658B2 NZ614658A NZ61465812A NZ614658B2 NZ 614658 B2 NZ614658 B2 NZ 614658B2 NZ 614658 A NZ614658 A NZ 614658A NZ 61465812 A NZ61465812 A NZ 61465812A NZ 614658 B2 NZ614658 B2 NZ 614658B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- polypeptide
- antibody
- region
- human
- variant
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims description 552
- 108090001123 antibodies Proteins 0.000 title claims description 552
- 229920001184 polypeptide Polymers 0.000 claims abstract description 383
- 230000002829 reduced Effects 0.000 claims abstract description 111
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 82
- 238000006467 substitution reaction Methods 0.000 claims abstract description 77
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004471 Glycine Substances 0.000 claims abstract description 17
- 108010062119 complement 1q receptor Proteins 0.000 claims abstract description 15
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims abstract description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004475 Arginine Chemical group 0.000 claims abstract description 7
- 102100015541 FCGR3A Human genes 0.000 claims description 59
- 101710044656 FCGR3A Proteins 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 34
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 210000001772 Blood Platelets Anatomy 0.000 claims description 26
- 102100015545 FCGR2A Human genes 0.000 claims description 26
- 230000002776 aggregation Effects 0.000 claims description 22
- 238000004220 aggregation Methods 0.000 claims description 22
- 230000002349 favourable Effects 0.000 claims description 9
- 230000003213 activating Effects 0.000 claims description 7
- 108091006004 Fc-tagged proteins Proteins 0.000 claims description 2
- 230000027455 binding Effects 0.000 description 213
- 210000004027 cells Anatomy 0.000 description 182
- 239000000427 antigen Substances 0.000 description 89
- 108091007172 antigens Proteins 0.000 description 87
- 102000038129 antigens Human genes 0.000 description 87
- 102000005962 receptors Human genes 0.000 description 73
- 108020003175 receptors Proteins 0.000 description 73
- 235000001014 amino acid Nutrition 0.000 description 71
- 230000035772 mutation Effects 0.000 description 56
- 102000009109 Fc receptors Human genes 0.000 description 55
- 108010087819 Fc receptors Proteins 0.000 description 55
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 55
- 230000000694 effects Effects 0.000 description 51
- 102000004851 Immunoglobulin G Human genes 0.000 description 48
- 108090001095 Immunoglobulin G Proteins 0.000 description 48
- 238000004166 bioassay Methods 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 46
- 239000000203 mixture Substances 0.000 description 41
- 238000000034 method Methods 0.000 description 38
- 125000000539 amino acid group Chemical group 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 33
- 108010045030 monoclonal antibodies Proteins 0.000 description 33
- 102000005614 monoclonal antibodies Human genes 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 102000018358 Immunoglobulins Human genes 0.000 description 30
- 108060003951 Immunoglobulins Proteins 0.000 description 30
- 239000003446 ligand Substances 0.000 description 30
- 230000004048 modification Effects 0.000 description 30
- 238000006011 modification reaction Methods 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 28
- 108020004707 nucleic acids Proteins 0.000 description 28
- 230000003247 decreasing Effects 0.000 description 25
- 102100016531 CD9 Human genes 0.000 description 22
- 101700017162 CD9 Proteins 0.000 description 22
- 230000035492 administration Effects 0.000 description 22
- 102100014838 FCGRT Human genes 0.000 description 21
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 229960000060 monoclonal antibodies Drugs 0.000 description 21
- 101710003435 FCGRT Proteins 0.000 description 20
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 20
- 210000004408 Hybridomas Anatomy 0.000 description 19
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 18
- 101710044657 FCGR3B Proteins 0.000 description 17
- 238000003780 insertion Methods 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000000295 complement Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 230000035693 Fab Effects 0.000 description 15
- -1 excipient Substances 0.000 description 14
- 102100015543 FCGR2B Human genes 0.000 description 14
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 14
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 102000008212 P-Selectin Human genes 0.000 description 13
- 108010035766 P-Selectin Proteins 0.000 description 13
- 230000004075 alteration Effects 0.000 description 13
- 230000000051 modifying Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 101700009480 Fcgr3 Proteins 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 150000001720 carbohydrates Chemical class 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 102200025889 ALDH3A1 P329A Human genes 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 239000000562 conjugate Substances 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 229940088598 Enzyme Drugs 0.000 description 10
- 108010073807 IgG Receptors Proteins 0.000 description 10
- 102000009490 IgG Receptors Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 108091006028 chimera Proteins 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 230000001472 cytotoxic Effects 0.000 description 10
- 230000001419 dependent Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000001965 increased Effects 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 150000002482 oligosaccharides Polymers 0.000 description 10
- 230000002285 radioactive Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 210000001519 tissues Anatomy 0.000 description 10
- 230000036947 Dissociation constant Effects 0.000 description 9
- 108010027440 Immunoconjugates Proteins 0.000 description 9
- 102000018748 Immunoconjugates Human genes 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 9
- 206010057249 Phagocytosis Diseases 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229920001542 oligosaccharide Polymers 0.000 description 9
- 230000008782 phagocytosis Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- 231100000765 Toxin Toxicity 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 230000001404 mediated Effects 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 108020003112 toxins Proteins 0.000 description 8
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 7
- 210000003719 B-Lymphocytes Anatomy 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 230000024203 complement activation Effects 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 230000003899 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000000099 in vitro assay Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000002147 killing Effects 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 6
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 102100015540 FCGR1A Human genes 0.000 description 6
- 101710003440 FCGR1A Proteins 0.000 description 6
- 230000036499 Half live Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- 229920001850 Nucleic acid sequence Polymers 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 102100015249 VEGFA Human genes 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 230000001809 detectable Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000001264 neutralization Effects 0.000 description 6
- 229920001405 Coding region Polymers 0.000 description 5
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 5
- 102100016662 ERBB2 Human genes 0.000 description 5
- 101700025368 ERBB2 Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 5
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 5
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 5
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 5
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 229920000272 Oligonucleotide Polymers 0.000 description 5
- 101700014070 SDR Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 229940020899 hematological Enzymes Drugs 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000001976 improved Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010071919 Bispecific Antibodies Proteins 0.000 description 4
- 108009000280 Complement Activation Proteins 0.000 description 4
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 4
- 102100016790 HPRT1 Human genes 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
- 210000004379 Membranes Anatomy 0.000 description 4
- 210000001616 Monocytes Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000000440 Neutrophils Anatomy 0.000 description 4
- 108020005203 Oxidases Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 201000009030 carcinoma Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 108010047295 complement receptors Proteins 0.000 description 4
- 102000006834 complement receptors Human genes 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 200000000002 platelet activation Diseases 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052702 rhenium Inorganic materials 0.000 description 4
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 3
- 102100001249 ALB Human genes 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 230000003844 B-cell-activation Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 102100005826 CD19 Human genes 0.000 description 3
- 101700087100 CD19 Proteins 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 230000037250 Clearance Effects 0.000 description 3
- 108010069112 Complement System Proteins Proteins 0.000 description 3
- 102000000989 Complement System Proteins Human genes 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102100019442 ITGAL Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 3
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 101700009327 NTF3 Proteins 0.000 description 3
- 102100015697 NTF3 Human genes 0.000 description 3
- 210000001672 Ovary Anatomy 0.000 description 3
- 229940072417 Peroxidase Drugs 0.000 description 3
- 108090000437 Peroxidases Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 230000035969 Vmax Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000035512 clearance Effects 0.000 description 3
- 238000007374 clinical diagnostic method Methods 0.000 description 3
- 230000002860 competitive Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000000779 depleting Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000000242 pagocytic Effects 0.000 description 3
- 108091008117 polyclonal antibodies Proteins 0.000 description 3
- 230000003405 preventing Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000000717 retained Effects 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous Effects 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000001960 triggered Effects 0.000 description 3
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 2
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101700061329 ARTN Proteins 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 108091008154 B cell receptors Proteins 0.000 description 2
- 108090000363 Bacterial Luciferases Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 102100005310 CTLA4 Human genes 0.000 description 2
- 101700054183 CTLA4 Proteins 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940047120 Colony stimulating factors Drugs 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 2
- 108010015133 EC 1.1.3.9 Proteins 0.000 description 2
- 108010093894 EC 1.17.3.2 Proteins 0.000 description 2
- 101700033006 EGF Proteins 0.000 description 2
- 102100010813 EGF Human genes 0.000 description 2
- 101700041204 ERBB3 Proteins 0.000 description 2
- 102000027776 ERBB3 Human genes 0.000 description 2
- 101700023619 ERBB4 Proteins 0.000 description 2
- 102000027777 ERBB4 Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 2
- 102100015544 FCGR2C Human genes 0.000 description 2
- 102100015542 FCGR3B Human genes 0.000 description 2
- 101710009074 FLT3 Proteins 0.000 description 2
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 2
- 208000005017 Glioblastoma Diseases 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 101710006573 ITGAL Proteins 0.000 description 2
- 108090001122 Immunoglobulin A Proteins 0.000 description 2
- 231100000608 Immunotoxin Toxicity 0.000 description 2
- 108010004484 Immunotoxins Proteins 0.000 description 2
- 102400000022 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 229940047122 Interleukins Drugs 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 229940057428 LACTOPEROXIDASE Drugs 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000028880 Lactoperoxidase Human genes 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100008175 MGAM Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102100016138 NTF4 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229940068977 Polysorbate 20 Drugs 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 229960000856 Protein C Drugs 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000491 Small cell lung cancer Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 102100014320 TGFB1 Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 240000004652 Vaccinium ovalifolium Species 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 102100002634 XDH Human genes 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003466 anti-cipated Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 108091008116 antibody drug conjugates Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229910052789 astatine Inorganic materials 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal Effects 0.000 description 2
- 201000011231 colorectal cancer Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001461 cytolytic Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 230000002498 deadly Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003292 diminished Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000002538 fungal Effects 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 108010029942 microperoxidase Proteins 0.000 description 2
- 108060005018 mobB Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive Effects 0.000 description 2
- 125000001235 proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 231100000224 toxic side effect Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- WGMMKWFUXPMTRW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-bromoacetyl)amino]propanoate Chemical compound BrCC(=O)NCCC(=O)ON1C(=O)CCC1=O WGMMKWFUXPMTRW-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-hydroxypropanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- HABAJMUFCIDFOT-JEDNCBNOSA-M (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;acetate Chemical compound CC([O-])=O.OC(=O)[C@@H](N)CC1=CN=CN1 HABAJMUFCIDFOT-JEDNCBNOSA-M 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- LCZVQHWMSQLWSC-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O LCZVQHWMSQLWSC-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- OBWSOTREAMFOCQ-UHFFFAOYSA-N 4-(4-amino-3,5-dimethylphenyl)-2,6-dimethylaniline;hydrochloride Chemical compound Cl.CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 OBWSOTREAMFOCQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- TUTIHHSZKFBMHM-UHFFFAOYSA-N 4-amino-5-[(3-amino-1-carboxy-3-oxopropyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O TUTIHHSZKFBMHM-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710006356 ACTI Proteins 0.000 description 1
- 102100014858 AMH Human genes 0.000 description 1
- 101710026933 AMH Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
- NPDLYUOYAGBHFB-UHFFFAOYSA-N Asparaginyl-Arginine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N NPDLYUOYAGBHFB-UHFFFAOYSA-N 0.000 description 1
- QJMCHPGWFZZRID-UHFFFAOYSA-N Asparaginyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(N)=O QJMCHPGWFZZRID-UHFFFAOYSA-N 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 241000590572 Bia <butterfly> Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000004899 C-terminal region Anatomy 0.000 description 1
- 101700043583 CCR5 Proteins 0.000 description 1
- 102100012080 CCR5 Human genes 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 102100019450 CD81 Human genes 0.000 description 1
- 101700062651 CD81 Proteins 0.000 description 1
- 101710041060 COX7A1 Proteins 0.000 description 1
- 229920002574 CR-39 Polymers 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 101700046715 CSTI Proteins 0.000 description 1
- 101710025651 CXCR5 Proteins 0.000 description 1
- 102100002072 CXCR5 Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 101700020566 DEFA4 Proteins 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000035687 Dissociation Rate Constant Effects 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N Disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N Dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000009071 ErbB Receptors Human genes 0.000 description 1
- 108010073043 ErbB Receptors Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 102100006624 F9 Human genes 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 230000036809 Fabs Effects 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 101700050236 Fcgr4 Proteins 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101700032815 GALNS Proteins 0.000 description 1
- 102100020232 GALNS Human genes 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 101710044881 GHRH Proteins 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- SSHIXEILTLPAQT-UHFFFAOYSA-N Glutaminyl-Aspartate Chemical compound NC(=O)CCC(N)C(=O)NC(CC(O)=O)C(O)=O SSHIXEILTLPAQT-UHFFFAOYSA-N 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 101700063555 HYAL Proteins 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000001974 Hyaluronidase Human genes 0.000 description 1
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 1
- 229940044700 Hylenex Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101710006353 IP3R Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 101700035656 ISOTI Proteins 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 102100001475 ITGB2 Human genes 0.000 description 1
- 101710006663 ITGB2 Proteins 0.000 description 1
- 101700035039 ITI Proteins 0.000 description 1
- 101700052013 ITR2 Proteins 0.000 description 1
- 101700068039 ITRP Proteins 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 229940055742 Indium-111 Drugs 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 101800001819 Insulin A chain Proteins 0.000 description 1
- 102400000453 Insulin A chain Human genes 0.000 description 1
- 101800000896 Insulin B chain Proteins 0.000 description 1
- 102400000454 Insulin B chain Human genes 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N L-tyrosyl-L-tyrosine Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 210000002664 Langerhans' cell Anatomy 0.000 description 1
- DXOJIXGRFSHVKA-BZVZGCBYSA-N Larotaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 DXOJIXGRFSHVKA-BZVZGCBYSA-N 0.000 description 1
- 229950005692 Larotaxel Drugs 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 229940040129 Luteinizing Hormone Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 101710027015 MIMI_R382 Proteins 0.000 description 1
- 101700013924 MITF Proteins 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 101700036939 MTI Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 240000004175 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- 102100009139 NGF Human genes 0.000 description 1
- 101700079360 NTF4 Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 229940032018 Neurotrophin 3 Drugs 0.000 description 1
- 108090000742 Neurotrophin-3 Proteins 0.000 description 1
- 102000004230 Neurotrophin-3 Human genes 0.000 description 1
- 229920002649 Nonsense suppressor Polymers 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N Ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229950001094 Ortataxel Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 210000004303 Peritoneum Anatomy 0.000 description 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 108010006545 Plantibodies Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 231100000654 Protein toxin Toxicity 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 102100000775 REN Human genes 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 101710004305 RIP30A Proteins 0.000 description 1
- 101700000014 RIPS Proteins 0.000 description 1
- 101710002944 RLN Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 101800000074 Relaxin A chain Proteins 0.000 description 1
- 102400000834 Relaxin A chain Human genes 0.000 description 1
- 102400000610 Relaxin B chain Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100004182 SPAM1 Human genes 0.000 description 1
- 101710016618 SPAM1 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 108010055514 Streptococcus IgG Fc-binding protein Proteins 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 101700038204 TGFA Proteins 0.000 description 1
- 101700041213 TGFB1 Proteins 0.000 description 1
- 101700062451 TI Proteins 0.000 description 1
- 101700057439 TOXA Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N Tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 Tesetaxel Drugs 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N Texas Red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- IQPTVTKRJHUUGI-UHFFFAOYSA-N [[1-(2,5-dioxopyrrolidin-1-yl)-2H-pyridin-2-yl]disulfanyl] propanoate Chemical compound CCC(=O)OSSC1C=CC=CN1N1C(=O)CCC1=O IQPTVTKRJHUUGI-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 108010049535 anti-IgE antibodies Proteins 0.000 description 1
- 230000001455 anti-clotting Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001219 anucleate thrombocyte Anatomy 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 101700067277 chxA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960004222 factor IX Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imido esters Chemical class 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 108010082095 insulin-like growth factor 1, des-(1-3)- Proteins 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 101700063896 mac-1 Proteins 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010031099 mannose receptor Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 102000035365 modified proteins Human genes 0.000 description 1
- 108091005569 modified proteins Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 108010087335 neurotrophin 5 Proteins 0.000 description 1
- 108090000095 neurotrophin 6 Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 101710015766 ngl Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001293 nucleolytic Effects 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002138 osteoinductive Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001902 propagating Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000001743 silencing Effects 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- HHSGWIABCIVPJT-UHFFFAOYSA-M sodium;1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 HHSGWIABCIVPJT-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 108060005723 speA Proteins 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108010042974 transforming growth factor beta4 Proteins 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecenes Natural products 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- VOBHRQFELWTZFS-AWLRYRRCSA-K trisodium;(4Z)-3-oxo-4-[(4-sulfonatonaphthalen-1-yl)hydrazinylidene]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N/N=C3/C4=CC=C(C=C4C=C(C3=O)S(=O)(=O)[O-])S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 VOBHRQFELWTZFS-AWLRYRRCSA-K 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N β-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Abstract
Discloses a polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising an amino acid substitution at position Pro329, wherein Pro329 of a wild-type human Fc region is substituted with glycine or arginine, and wherein the Fc variant comprises at least two further amino acid substitutions, wherein said further amino acid substitutions are L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region, wherein the residues are numbered according to the EU index of Kabat, and wherein said polypeptide exhibits an at least 10-fold reduced affinity to the human Fc?RIIIA and a reduced affinity to the human, Fc?RIIA, Fc?RI and the human C1q receptor, compared to a polypeptide comprising the wildtype IgG Fc region, and wherein the ADCC induced by said polypeptide is reduced to 0-20% of the ADCC induced by the polypeptide comprising a wild-type human IgG Fc region. Also discloses use of the Fc region for down-modulation of ADCC or ADCP. her amino acid substitutions, wherein said further amino acid substitutions are L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region, wherein the residues are numbered according to the EU index of Kabat, and wherein said polypeptide exhibits an at least 10-fold reduced affinity to the human Fc?RIIIA and a reduced affinity to the human, Fc?RIIA, Fc?RI and the human C1q receptor, compared to a polypeptide comprising the wildtype IgG Fc region, and wherein the ADCC induced by said polypeptide is reduced to 0-20% of the ADCC induced by the polypeptide comprising a wild-type human IgG Fc region. Also discloses use of the Fc region for down-modulation of ADCC or ADCP.
Description
Field of the invention
The present invention concerns polypeptides comprising variants of an Fc region.
More particularly, the present invention concerns Fc region-containing
polypeptides that have altered effector function as a consequence of one or more
amino acid substitutions in the Fc region of the polypeptide.
Summary
The present invention relates to the field of antibody variants and provides
polypeptides comprising Fc variants with a decreased effector function, like
decreased ADCC and/or C1q binding.
In particular the invention provides a polypeptide comprising an Fc variant of a
wild-type human IgG Fc region, said Fc variant comprising an amino acid
substitution at position Pro329, wherein Pro329 of a wild-type human Fc region is
substituted with glycine or arginine, and wherein the Fc variant comprises at least
two further amino acid substitutions, wherein said further amino acid substitutions
are L234A and L235A of the human IgG1 Fc region or S228P and L235E of the
human IgG4 Fc region, wherein the residues are numbered according to the EU
index of Kabat, and wherein said polypeptide exhibits an at least 10-fold reduced
affinity to the human FcγRIIIA and a reduced affinity to the human, FcγRIIA,
FcγRI and the human C1q receptor, compared to a polypeptide comprising the
wildtype IgG Fc region, and wherein the ADCC induced by said polypeptide is
reduced to 0-20% of the ADCC induced by the polypeptide comprising a wild-type
human IgG Fc region.
In the polypeptides of the invention, Pro329 of a wild-type human Fc region in the
polypeptide described above is substituted with glycine or arginine, and at least two
further amino acid substitutions, which are L234A and L235A of the human IgG1
Fc region or S228P and L235E of the human IgG4 Fc region.
In another aspect of the invention the polypeptide comprises a human IgG1 or IgG4
Fc region. In still another aspect of the invention the polypeptide is an antibody or
an Fc fusion protein.
In a further embodiment the thrombocyte aggregation induced by the polypeptide
comprising the Fc variant is reduced compared to the thrombocyte aggregation
induced by a polypeptide comprising a wild-type human IgG Fc region. In still a
further embodiment, the polypeptide according to the invention exhibits a strongly
reduced CDC compared to the CDC induced by a polypeptide comprising a wild-
type human IgG Fc region.
In another embodiment of the invention polypeptides comprising an Fc variant, as
described above, are provided for use as a medicament. In a specific embodiment
the polypeptide is an anti-CD9 antibody, which is characterized in that the
polypeptide comprising the wildtype Fc region comprises as heavy chain variable
region SEQ ID NO:9 and as variable light chain region SEQ ID NO:8.
In another aspect of the invention the polypeptides as described above are provided
for use in treating a disease wherein it is favorable that an effector function of the
polypeptide comprising the Fc variant is strongly reduced compared to the effector
function induced by a polypeptide comprising a wild-type human IgG Fc region.
In another embodiment the use of the polypeptides as described above is provided
for the manufacture of a medicament for the treatment of a disease, wherein it is
favorable that the effector function of the polypeptide comprising an Fc variant of a
wild-type human IgG Fc region is strongly reduced compared to the effector
function induced by a polypeptide comprising a wild-type human IgG Fc region.
Also described herein is a method of treating an individual having a disease,
wherein it is favorable that the effector function of the polypeptide comprising an
Fc variant of a wild-type human IgG Fc region is strongly reduced compared to the
effector function induced by a polypeptide comprising a wildtype human Fc
polypeptide, comprising administering to an individual an effective amount of the
polypeptide described above.
Another aspect of the invention is use of a polypeptide comprising an Fc variant of
a wild-type human IgG Fc region, said polypeptide having Pro329 of the human
IgG Fc region substituted with glycine and wherein the Fc variant comprises at
least two further amino acid substitutions at L234A and L235A of the human IgG1
Fc region or S228P and L235E of the human IgG4 Fc region, wherein the residues
are numbered according to the EU index of Kabat, wherein said polypeptide
exhibits a reduced affinity to the human FcγRIIIA and FcγRIIA, in the manufacture
of a medicament for down-modulation of ADCC to 0-20% of the ADCC induced
by the polypeptide comprising the wildtype human IgG Fc region, and/or for down-
modulation of ADCP.
Another aspect of the invention is use of the polypeptide described above, wherein
the thrombocyte aggregation induced by the polypeptide described above is
reduced compared to the thrombocyte aggregation induced by a polypeptide
comprising a wildtype human Fc region, wherein the polypeptide is a platelet
activating antibody.
Also described herein is a method of treating an individual having a disease,
wherein said individual is treated with a polypeptide, said polypeptide having
Pro329 of the human IgG Fc region substituted with glycine and at least two
further amino acid substitutions at L234A and L235A of the human IgG1 Fc region
or S228P and L235E of the human IgG4 Fc region, wherein the residues are
numbered according to the EU index of Kabat, wherein said polypeptide is
characterized by a strongly reduced binding to FcγRIIIA and FcγRIIA compared to
a polypeptide comprising a wildtype human IgG Fc region, comprising
administering to the individual an effective amount of said polypeptide.
The invention is as defined in the claims. However, the description which follows
also refers to additional polypeptides and uses thereof outside the scope of the
current claims. This description is retained for technical information.
Background
Monoclonal antibodies have great therapeutic potential and play an important role
in today’s medical portfolio. During the last decade, a significant trend in the
pharmaceutical industry has been the development of monoclonal antibodies
(mAbs) as therapeutic agents for the treatment of a number of diseases, such as
cancers, asthma, arthritis, multiple sclerosis etc.. Monoclonal antibodies are
predominantly manufactured as recombinant proteins in genetically engineered
mammalian cell culture.
The Fc region of an antibody, i.e., the terminal ends of the heavy chains of
antibody spanning domains CH2, CH3 and a portion of the hinge region, is limited
in variability and is involved in effecting the physiological roles played by the
antibody. The effector functions attributable to the Fc region of an antibody vary
with the class and subclass of antibody and include binding of the antibody via the
Fc region to a specific Fc receptor ("FcR") on a cell which triggers various
biological responses.
These receptors typically have an extracellular domain that mediates binding to Fc,
a membrane spanning region, and an intracellular domain that may mediate some
signaling event within the cell. These receptors are expressed in a variety of
immune cells including monocytes, macrophages, neutrophils, dendritic cells,
eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans'
cells, natural killer (NK) cells, and T cells. Formation of the Fc/FcγR complex
recruits these effector cells to sites of bound antigen, typically resulting in signaling
events within the cells and important subsequent immune responses such as release
of inflammation mediators, B cell activation, endocytosis, phagocytosis, and
cytotoxic attack. The ability to mediate cytotoxic and phagocytic effector functions
is a potential mechanism by which antibodies destroy targeted cells. The cell-
mediated reaction wherein nonspecific cytotoxic cells that express FcγRs recognize
bound antibody on a target cell and subsequently cause lysis of the target cell is
referred to as antibody dependent cell-mediated cytotoxicity (ADCC) (Ravetch, et
al., Annu Rev Immunol 19 (2001) 275-290). The cell-mediated reaction wherein
nonspecific cytotoxic cells that express FcγRs recognize bound antibody on a target
cell and subsequently cause phagocytosis of the target cell is referred to as antibody
dependent cell-mediated phagocytosis (ADCP). In addition, an overlapping site on
the Fc region of the molecule also controls the activation of a cell independent
cytotoxic function mediated by complement, otherwise known as complement
dependent cytotoxicity (CDC).
For the IgG class of Abs, ADCC and ADCP are governed by engagement of the Fc
region with a family of receptors referred to as Fcγ receptors (FcγRs). In humans,
this protein family comprises FcγRI (CD64); FcγRII (CD32), including isoforms
FcγRIIA, FcγRIIB, and FcγRIIC; and FcγRIII (CD16), including isoforms
FcγRIIIA and FcγRIIIB (Raghavan, and Bjorkman, Annu. Rev. Cell Dev. Biol. 12
(1996) 181–220; Abes, et al., Expert Reviews VOL 5(6), (2009) 735-747). FcγRs
are expressed on a variety of immune cells, and formation of the Fc/FcγR complex
recruits these cells to sites of bound antigen, typically resulting in signaling and
subsequent immune responses such as release of inflammation mediators, B cell
activation, endocytosis, phagocytosis, and cytotoxic attack. Furthermore, whereas
FcγRI, FcγRIIA/c, and FcγRIIIA are activating receptors characterized by an
intracellular immunoreceptor tyrosine-based activation motif (ITAM), FcγRIIB has
an inhibition motif (ITIM) and is therefore inhibitory. Moreover, de Reys, et al.,
Blood, 81, (1993) 1792-1800 concluded that platelet activation and aggregation
induced by monoclonal antibodies, like for example CD9, is initiated by antigen
recognition followed by an Fc domain dependent step, which involves the FcγRII-
receptor (see also: Taylor, et al., Blood 96 (2000) 4254-4260). While FcγRI binds
monomeric IgG with high affinity, FcγRIII and FcγRII are low-affinity receptors,
interacting with complexed or aggregated IgG.
The complement inflammatory cascade is a part of the innate immune response and
is crucial to the ability for an individual to ward off infection. Another important Fc
ligand is the complement protein C1q. Fc binding to C1q mediates a process called
complement dependent cytotoxicity (CDC). C1q is capable of binding six
antibodies, although binding to two IgGs is sufficient to activate the complement
cascade. C1q forms a complex with the C1r and C1s serine proteases to form the Cl
complex of the complement pathway.
In many circumstances, the binding and stimulation of effector functions mediated
by the Fc region of immunoglobulins is highly beneficial, e.g. for a CD20 antibody,
however, in certain instances it may be more advantageous to decrease or even to
eliminate the effector function. This is particularly true for those antibodies
designed to deliver a drug (e.g., toxins and isotopes) to the target cell where the
Fc/FcγR mediated effector functions bring healthy immune cells into the proximity
of the deadly payload, resulting in depletion of normal lymphoid tissue along with
the target cells (Hutchins, et al., PNAS USA 92 (1995) 11980-11984; White, et al.,
Annu Rev Med 52 (2001) 125-145). In these cases the use of antibodies that poorly
recruit complement or effector cells would be of a tremendous benefit (see also,
Wu, et al., Cell Immunol 200 (2000) 16-26; Shields, et al., J. Biol Chem 276(9)
(2001) 6591-6604; US 6,194,551; US 5,885,573 and PCT publication
WO 04/029207).
In other instances, for example, where blocking the interaction of a widely
expressed receptor with its cognate ligand is the objective, it would be
advantageous to decrease or eliminate all antibody effector function to reduce
unwanted toxicity. Also, in the instance where a therapeutic antibody exhibited
promiscuous binding across a number of human tissues it would be prudent to limit
the targeting of effector function to a diverse set of tissues to limit toxicity. Last but
not least, reduced affinity of antibodies to the FcγRII receptor in particular would
be advantageous for antibodies inducing platelet activation and aggregation via
FcγRII receptor binding, which would be a serious side-effect of such antibodies.
Although there are certain subclasses of human immunoglobulins that lack specific
effector functions, there are no known naturally occurring immunoglobulins that
lack all effector functions. An alternate approach would be to engineer or mutate
the critical residues in the Fc region that are responsible for effector function. For
examples see PCT publications (Medimmune),
(Xencor), (Univ. Cambridge),
US 2006/0134709 (Macrogenics), (Xencor),
(Xencor), US 6,737,056 (Genentech), US 5,624,821 (Scotgen Pharmaceuticals),
and US 2010/0166740 (Roche).
The binding of IgG to activating and inhibitory Fcγ receptors or the first
component of complement (C1q) depends on residues located in the hinge region
and the CH2 domain. Two regions of the CH2 domain are critical for FcγRs and
complement C1q binding, and have unique sequences. Substitution of human IgG1
and IgG2 residues at positions 233-236 and IgG4 residues at positions 327, 330 and
331 greatly reduced ADCC and CDC (Armour, et al., Eur. J. Immunol. 29(8)
(1999) 2613-2624; Shields, et al., J. Biol. Chem. 276(9) (2001) 6591-6604).
Idusogie, et al., J. Immunol 166 (2000) 2571-2575) mapped the C1q binding site
for rituxan and showed that Pro329Ala reduced the ability of Rituximab to bind
C1q and activate complement. Substitution of Pro329 with Ala has been reported to
lead to a reduced binding to the FcγRI, FcγRII and FcγRIIIA receptors (Shields, et
al., J. Biol. Chem. 276(9) (2001) 6591-6604) but this mutation has also been
described as exhibiting a wildtype-like binding to the FcγRI and FcγRII and only a
very small decrease in binding to the FcγRIIIA receptor (Table 1 and Table 2 in
EP 1 068 241, Genentech).
Oganesyan, et al., Acta Cristallographica D64 (2008) 700-704 introduced the triple
mutation L234F/L235E/P331S into the lower hinge and C2H domain and showed a
decrease in binding activity to human IgG1 molecules to human C1q receptor,
FcγRI, FcγRII and FcγRIIIA.
Still, there is an unmet need for antibodies with a strongly decreased ADCC and/or
ADCP and/or CDC. Therefore, the aim of the current invention was to identify
such antibodies. Surprisingly, it has been found that mutating the proline residue at
Pro329 to glycine resulted in an unexpected strong inhibition of the FcγRIIIA and
FcγRIIA receptor and in a strong inhibition of ADCC and CDC. Moreover, the
combined mutation of Pro329 and for example L234A and L235A (LALA) lead to
an unexpected strong inhibition of C1q, FcγRI, FcγRII and FcγRIIIA. Thus, a
glycine residue appears to be unexpectedly superior over other amino acid
substitutions, like alanine, for example, at position 329 in destroying the proline
sandwich in the Fc/Fcγ receptor interface.
Description of the Figures
Figure 1
Binding affinities of different FcγRs towards immunoglobulins were measured by
Surface Plasmon Resonance (SPR) using a Biacore T100 instrument (GE
Healthcare) at 25°C.
a) FcγRI binding affinity was tested for GA101 (GA) antibody variants (IgG1-
P329G, IgG4-SPLE and IgG1-LALA mutation) and for P-selectin (PS)
antibody variants (IgG1-P329G, IgG1-LALA and IgG4-SPLE) as well as for
the wildtype antibodies.
b) FcγRI binding affinity was tested for CD9 antibody variants (IgG1-wildtype,
IgG1-P329G, IgG1-LALA, IgG4-SPLE, IgG1-P329G / LALA, IgG4-SPLE /
P329G) as well as for the wildtype antibodies.
c) FcγRIIA(R131) binding affinity was tested for CD9 antibody variants (IgG1-
wildtype, IgG1-P329G, IgG1-LALA, IgG4-SPLE, IgG1-P329G/ LALA, IgG4-
SPLE / P329G) as well as for the wildtype antibodies. A normalized response is
shown as a function of the concentration of the receptor.
d) FcγRIIB binding affinity was tested for CD9 (named here:”TA”) antibody
variants (IgG1-wildtype, IgG4-SPLE / P329G, IgG1-LALA, IgG1–LALA /
P329G) and P-selectin (pSel) antibody variants (IgG4-wildtype, IgG4-SPLE) as
well as for the wildtype antibodies.
e) FcγRIIIA-V158 binding affinity was tested for CD9 antibody variants (IgG1-
wildtype, IgG4-SPLE, IgG1-LALA, IgG4-SPLE / P329G, IgG1-P329G, IgG1-
LALA / P329G) as well as for the wildtype antibodies. a normalized response
is shown as a function of the concentration of the receptor.
Figure 2
C1q binding was tested for P-selectin (PS) antibody variants (IgG1 wildtype,
P329G, IgG4-SPLE) and CD20 (GA) antibody variants (IgG1-wildtype, P329G
and IgG4-SPLE).
Figure 3
Potency to recruit immune-effector cells depends on type of Fc variant. Fc variants
were coated on an ELISA plate and human NK92 effector cells transfected with
human FcγRIIIA were added. Induction of cytolytic activity of activated NK cells
was measured using an esterase assay.
a) CD20 (GA101) antibody variants (wildtype, LALA, P329G, P329G /
LALA) were analyzed. b) CD20 (GA101) antibody variants (P329R or
P329G mutations introduced) were analyzed. . All variants were produced
in the glycoengineered version in order to have a stronger signal for any
effector cell recruitment function.
Figure 4
Potency to recruit immune-effector cells depends on type of Fc variant, as
measured by classical ADCC assay. Human NK92 cell-line transfected with human
FγcRIIIA was used as effector and CD20 positive Raji cells were used as target
cells. Different glycengineered CD20 antibody (GA101 G(2) and non-
glycoengineered CD20 antibody (GA101) variants (P329G, P329A or LALA
mutations introduced) were tested.
a) non-glycoengineered CD20 antibody : P329G, LALA and P329G/LALA
mutations, respectively, have been introduced into the antibody,
respectively.
b) glycoengineered CD20 antibody: P329G, P329A and LALA mutations,
respectively, have been introduced into the antibody, respectively.
Figure 5
Complement dependent cytotoxicity (CDC) assay. The different Fc variants of a
non-glycoengineered and glycoengineered CD20 (GA101) antibody were analyzed
for their efficacy to mediate CDC on SUDH-L4 target cells.
a) non-glycoengineered CD20: P329G, LALA and P329G/LALA mutations,
respectively, have been introduced into the antibody, respectively.
b) glycoengineered CD20: P329G, P329A and LALA mutations, respectively,
have been introduced into the antibody, respectively.
Figure 6
a) Carbohydrate profile of Fc-associated glycans of human IgG1 variants. The
percentage of galactosylation on Fc-associated oligosacchrides of hIgG1
containing the LALA, P329G, P329A or P329G / LALA mutations only differs
minimally from that of wild type antibody.
b) Relative galactosylation: Four different IgGs with introduced IgG1 P329G /
LALA mutations. Four different V-domains were compared for their amount of
galactosylation when expressed in Hek293 EBNA cells.
Figure 7
Antibody-induced platelet aggregation in whole blood assay. Murine IgG1 induced
platelet aggregation as determined for two donors differing in their response in
dependence of the antibody concentration.
a) Donor A, b) Donor B.
Detailed Description of the Invention
Definitions
In the present specification and claims, the numbering of the residues in an
immunoglobulin heavy chain is that of the EU index as in Kabat, et al., Sequences
of Proteins of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by
reference. The “EU index as in Kabat” refers to the residue numbering of the
human IgG1 EU antibody.
“Affinity” refers to the strength of the sum total of noncovalent interactions
between a single binding site of a molecule (e.g., an antibody) and its binding
partner (e.g., an antigen or an Fc receptor). Unless indicated otherwise, as used
herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1
interaction between members of a binding pair (e.g., antibody/Fc receptor or
antibody and antigen). The affinity of a molecule X for its partner Y can generally
be represented by the dissociation constant (Kd). Affinity can be measured by
common methods known in the art, including those described herein. Specific
illustrative and exemplary embodiments for measuring binding affinity are
described in the following.
An “affinity matured” antibody refers to an antibody with one or more alterations
in one or more hypervariable regions (HVRs), compared to a parent antibody
which does not possess such alterations, such alterations resulting in an
improvement in the affinity of the antibody for antigen.
An “amino acid modification” refers to a change in the amino acid sequence of a
predetermined amino acid sequence. Exemplary modifications include an amino
acid substitution, insertion and/or deletion. The preferred amino acid modification
herein is a substitution. An “amino acid modification at” a specified position, e.g.
of the Fc region, refers to the substitution or deletion of the specified residue, or the
insertion of at least one amino acid residue adjacent the specified residue. By
insertion “adjacent” a specified residue is meant insertion within one to two
residues thereof. The insertion may be N-terminal or C-terminal to the specified
residue.
An “amino acid substitution” refers to the replacement of at least one existing
amino acid residue in a predetermined amino acid sequence with another different
“replacement” amino acid residue. The replacement residue or residues may be
“naturally occurring amino acid residues” (i.e. encoded by the genetic code) and
selected from the group consisting of: alanine (Ala); arginine (Arg); asparagine
(Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gln); glutamic acid (Glu);
glycine (Gly); histidine (His); isoleucine (Ile): leucine (Leu); lysine (Lys);
methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr);
tryptophan (Trp); tyrosine (Tyr); and valine (Val). Preferably, the replacement
residue is not cysteine. Substitution with one or more non-naturally occurring
amino acid residues is also encompassed by the definition of an amino acid
substitution herein. A “non-naturally occurring amino acid residue” refers to a
residue, other than those naturally occurring amino acid residues listed above,
which is able to covalently bind adjacent amino acid residues(s) in a polypeptide
chain. Examples of non-naturally occurring amino acid residues include norleucine,
ornithine, norvaline, homoserine and other amino acid residue analogues such as
those described in Ellman, et al., Meth. Enzym. 202 (1991) 301-336. To generate
such non-naturally occurring amino acid residues, the procedures of Noren, et al.,
Science 244 (1989) 182 and Ellman, et al., supra, can be used. Briefly, these
procedures involve chemically activating a suppressor tRNA with a non-naturally
occurring amino acid residue followed by in vitro transcription and translation of
the RNA.
An “amino acid insertion” refers to the incorporation of at least one amino acid into
a predetermined amino acid sequence. While the insertion will usually consist of
the insertion of one or two amino acid residues, the present application
contemplates larger “peptide insertions”, e.g. insertion of about three to about five
or even up to about ten amino acid residues. The inserted residue(s) may be
naturally occurring or non-naturally occurring as disclosed above.
An “amino acid deletion” refers to the removal of at least one amino acid residue
from a predetermined amino acid sequence.
The term "antibody" herein is used in the broadest sense and encompasses various
antibody structures, including but not limited to monoclonal antibodies, polyclonal
antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody
fragments so long as they exhibit the desired antigen-binding activity.
The term “antibody variant” as used herein refers to a variant of a wildtype
antibody, characterized in that an alteration in the amino acid sequence relative to
the wildtype antibody occurs in the antibody variant, e.g. introduced by mutations a
specific amino acid residues in the wildtype antibody.
The term “antibody effector function(s),” or “effector function” as used herein
refers to a function contributed by an Fc effector domain(s) of an IgG (e.g., the Fc
region of an immunoglobulin). Such function can be effected by, for example,
binding of an Fc effector domain(s) to an Fc receptor on an immune cell with
phagocytic or lytic activity or by binding of an Fc effector domain(s) to
components of the complement system. Typical effector functions are ADCC,
ADCP and CDC.
An "antibody fragment" refers to a molecule other than an intact antibody that
comprises a portion of an intact antibody that binds the antigen to which the intact
antibody binds. Examples of antibody fragments include but are not limited to Fv,
Fab, Fab', Fab’-SH, F(ab') ; diabodies; linear antibodies; single-chain antibody
molecules (e.g. scFv); and multispecific antibodies formed from antibody
fragments.
An “antibody that binds to the same epitope” as a reference antibody refers to an
antibody that blocks binding of the reference antibody to its antigen in a
competition assay by 50% or more, and conversely, the reference antibody blocks
binding of the antibody to its antigen in a competition assay by 50% or more. An
exemplary competition assay is provided herein.
“Antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to a cell-
mediated reaction in which nonspecific cytotoxic cells that express FcRs (e.g.
Natural Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody
on a target cell and subsequently cause lysis of the target cell. The primary cells for
mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express
FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized
in Table 3 on page 464 of Ravetch, and Kinet, Annu. Rev. Immunol 9 (1991) 457-
492.
The term “Antibody-dependent cellular phagocytosis” and “ADCP” refer to a
process by which antibody-coated cells are internalized, either in whole or in part,
by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells)
that bind to an immunoglobulin Fc region.
The term “binding domain” refers to the region of a polypeptide that binds to
another molecule. In the case of an FcR, the binding domain can comprise a
portion of a polypeptide chain thereof (e.g. the α chain thereof) which is
responsible for binding an Fc region. One useful binding domain is the
extracellular domain of an FcR α chain.
The term “binding” to an Fc receptor used herein means the binding of the
antibody to a Fc receptor in a BIAcore(R) assay for example (Pharmacia Biosensor
AB, Uppsala, Sweden).
In the BIAcore(R) assay the Fc receptor is bound to a surface and binding of the
variant, e.g. the antibody variant to which mutations have been introduced, is
measured by Surface Plasmon Resonance (SPR). The affinity of the binding is
defined by the terms ka (rate constant for the association of the antibody from the
antibody/Fc receptor complex), kd (dissociation constant), and KD (kd/ka).
Alternatively, the binding signal of a SPR sensogram can be compared directly to
the response signal of a reference, with respect to the resonance signal height and
the dissociation behaviors.
“C1q” is a polypeptide that includes a binding site for the Fc region of an
immunoglobulin. C1q together with two serine proteases, C1r and C1s, forms the
complex C1, the first component of the complement dependent cytotoxicity (CDC)
pathway. Human C1q can be purchased commercially from, e.g. Quidel, San
Diego, Calif..
The “CH2 domain” of a human IgG Fc region (also referred to as “Cγ2” domain)
usually extends from about amino acid 231 to about amino acid 340. The CH2
domain is unique in that it is not closely paired with another domain. Rather, two
N-linked branched carbohydrate chains are interposed between the two CH2
domains of an intact native IgG molecule. It has been speculated that the
carbohydrate may provide a substitute for the domain-domain pairing and help
stabilize the CH2 domain (Burton, Molec. Immunol. 22 (1985) 161-206).
The “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain
in an Fc region (i.e. from about amino acid residue 341 to about amino acid residue
447 of an IgG).
The terms “cancer” and “cancerous” refer to or describe the physiological
condition in mammals that is typically characterized by unregulated cell growth.
Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma,
sarcoma, and leukemia. More particular examples of such cancers include
squamous cell cancer, small-cell lung cancer, non-small cell lung cancer,
adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the
peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer,
glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer,
hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine
carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer,
vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and
neck cancer.
As used herein, the expressions “cell,” “cell line,” and “cell culture” are used
interchangeably and all such designations include progeny. Thus, the words
“transformants” and “transformed cells” include the primary subject cell and
cultures derived there from without regard for the number of transfers. It is also
understood that all progeny may not be precisely identical in DNA content, due to
deliberate or inadvertent mutations. Mutant progeny that have the same function or
biological activity as screened for in the originally transformed cell are included.
Where distinct designations are intended, it will be clear from the context.
The term "chimeric" antibody refers to an antibody in which a portion of the heavy
and/or light chain is derived from a particular source or species, while the
remainder of the heavy and/or light chain is derived from a different source or
species.
The “class” of an antibody refers to the type of constant domain or constant region
possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD,
IgE, IgG, and IgM, and several of these may be further divided into subclasses
(isotypes), e.g., IgG , IgG , IgG , IgG , IgA , and IgA . The heavy chain constant
1 2 3 4 1 2
domains that correspond to the different classes of immunoglobulins are called α,
δ, ε, γ, and μ, respectively.
The term "cytotoxic agent" as used herein refers to a substance that inhibits or
prevents a cellular function and/or causes cell death or destruction. Cytotoxic
211 131 125 90
agents include, but are not limited to, radioactive isotopes (e.g., At , I , I , Y ,
186 188 153 212 32 212
Re , Re , Sm , Bi , P , Pb and radioactive isotopes of Lu);
chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids
(vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C,
chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents;
enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins
such as small molecule toxins or enzymatically active toxins of bacterial, fungal,
plant or animal origin, including fragments and/or variants thereof; and the various
antitumor or anticancer agents disclosed below.
The term “complement-dependent cytotoxicity” or CDC refers to a mechanism for
inducing cell death in which an Fc effector domain(s) of a target-bound antibody
activates a series of enzymatic reactions culminating in the formation of holes in
the target cell membrane. Typically, antigen-antibody complexes such as those on
antibody-coated target cells bind and activate complement component C1q which
in turn activates the complement cascade leading to target cell death. Activation of
complement may also result in deposition of complement components on the target
cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on
leukocytes.
A “disorder” is any condition that would benefit from treatment with a polypeptide,
like antibodies comprising an Fc variant. This includes chronic and acute disorders
or diseases including those pathological conditions which predispose the mammal
to the disorder in question. In one embodiment, the disorder is cancer.
“Effector functions” refer to those biological activities attributable to the Fc region
of an antibody, which vary with the antibody isotype. Examples of antibody
effector functions include: C1q binding and complement dependent cytotoxicity
(CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity
(ADCC); phagocytosis (ADCP); down regulation of cell surface receptors (e.g. B
cell receptor); and B cell activation.
A “reduced effector function” as used herein refers to a reduction of a specific
effector function, like for example ADCC or CDC, in comparison to a control (for
example a polypeptide with a wildtype Fc region), by at least 20% and a “strongly
reduced effector function” as used herein refers to a reduction of a specific effector
function, like for example ADCC or CDC, in comparison to a control, by at least
50%.
An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an
amount effective, at dosages and for periods of time necessary, to achieve the
desired therapeutic or prophylactic result.
The term “Fc region” herein is used to define a C-terminal region of an
immunoglobulin heavy chain that contains at least a portion of the constant region.
The term includes native sequence Fc regions and variant Fc regions. In one
embodiment, a human IgG heavy chain Fc region extends from Cys226, or from
Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal
lysine (Lys447) of the Fc region may or may not be present. Unless otherwise
specified herein, numbering of amino acid residues in the Fc region or constant
region is according to the EU numbering system, also called the EU index, as
described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, MD (1991).
A “variant Fc region” comprises an amino acid sequence which differs from that of
a “native” or “wildtype” sequence Fc region by virtue of at least one “amino acid
modification” as herein defined. Preferably, the variant Fc region has at least one
amino acid substitution compared to a native sequence Fc region or to the Fc
region of a parent polypeptide, e.g. from about one to about ten amino acid
substitutions, and preferably from about one to about five amino acid substitutions
in a native sequence Fc region or in the Fc region of the parent polypeptide. The
variant Fc region herein will preferably possess at least about 80% homology with
a native sequence Fc region and/or with an Fc region of a parent polypeptide, and
most preferably at least about 90% homology therewith, more preferably at least
about 95% homology therewith.
The term “Fc-variant” as used herein refers to a polypeptide comprising a
modification in an Fc domain. The Fc variants of the present invention are defined
according to the amino acid modifications that compose them. Thus, for example,
P329G is an Fc variant with the substitution of proline with glycine at position 329
relative to the parent Fc polypeptide, wherein the numbering is according to the EU
index.. The identity of the wildtype amino acid may be unspecified, in which case
the aforementioned variant is referred to as P329G. For all positions discussed in
the present invention, numbering is according to the EU index. The EU index or
EU index as in Kabat or EU numbering scheme refers to the numbering of the EU
antibody (Edelman, et al., Proc Natl Acad Sci USA 63 (1969) 78-85, hereby
entirely incorporated by reference.) The modification can be an addition, deletion,
or substitution. Substitutions can include naturally occurring amino acids and non-
naturally occurring amino acids. Variants may comprise non-natural amino acids.
Examples include U.S. Pat. No. 6,586,207; WO 98/48032; WO 03/073238;
US 2004/0214988 A1; WO 05/35727 A2; WO 05/74524 A2; Chin, J.W., et al.,
Journal of the American Chemical Society 124 (2002) 9026-9027; Chin, J.W., and
Schultz, P.G., ChemBioChem 11 (2002) 1135-1137; Chin, J.W., et al., PICAS
United States of America 99 (2002) 11020-11024; and, Wang, L., and Schultz,
P.G., Chem. (2002) 1-10, all entirely incorporated by reference.
The term “Fc region-containing polypeptide” refers to a polypeptide, such as an
antibody or immunoadhesin (see definitions below), which comprises an Fc region.
The terms “Fc receptor” or “FcR” are used to describe a receptor that binds to the
Fc region of an antibody. The preferred FcR is a native sequence human FcR.
Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor)
and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including
allelic variants and alternatively spliced forms of these receptors. FcγRII receptors
include FcγRIIA (an “activating receptor”) and FcγRIIB (an “inhibiting receptor”),
which have similar amino acid sequences that differ primarily in the cytoplasmic
domains thereof. Activating receptor FcγRIIA contains an immunoreceptor
tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting
receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif
(ITIM) in its cytoplasmic domain. (see review in Daëron, M., Annu. Rev.
Immunol. 15 (1997) 203-234). FcRs are reviewed in Ravetch, and Kinet, Annu.
Rev. Immunol 9 (1991) 457-492; Capel, et al., Immunomethods 4 (1994) 25-34;
and de Haas, et al., J. Lab. Clin. Med. 126 (1995) 330-41. Other FcRs, including
those to be identified in the future, are encompassed by the term “FcR” herein. The
term also includes the neonatal receptor, FcRn, which is responsible for the transfer
of maternal IgGs to the fetus (Guyer, et al., J. Immunol. 117 (1976) 587 and Kim,
et al., J. Immunol. 24 (1994) 249).
By “IgG Fc ligand” as used herein is meant a molecule, preferably a polypeptide,
from any organism that binds to the Fc region of an IgG antibody to form an Fc/Fc
ligand complex. Fc ligands include but are not limited to FcγRs, FcγRs, FcγRs,
FcRn, C1q, C3, mannan binding lectin, mannose receptor, staphylococcal protein
A, streptococcal protein G, and viral FcγR. Fc ligands also include Fc receptor
homologs (FcRH), which are a family of Fc receptors that are homologous to the
FcγRs (Davis, et al., Immunological Reviews 190 (2002) 123-136, entirely
incorporated by reference). Fc ligands may include undiscovered molecules that
bind Fc. Particular IgG Fc ligands are FcRn and Fc gamma receptors. By “Fc
ligand” as used herein is meant a molecule, preferably a polypeptide, from any
organism that binds to the Fc region of an antibody to form an Fc/Fc ligand
complex.
By “Fc gamma receptor”, “FcγR” or “FcgammaR” as used herein is meant any
member of the family of proteins that bind the IgG antibody Fc region and is
encoded by an FcγR gene. In humans this family includes but is not limited to
FcγRI (CD64), including isoforms FcγRIA, FcγRIB, and FcγRIC; FcγRII (CD32),
including isoforms FcγRIIA (including allotypes H131 and R131), FcγRIIB
(including FcγRIIB-1 and FcγRIIB-2), and FcγRIIc; and FcγRIII (CD16), including
isoforms FcγRIIIA (including allotypes V158 and F158) and FcγRIIIb (including
allotypes FcγRIIB-NA1 and FcγRIIB-NA2) (Jefferis, et al., Immunol Lett 82
(2002) 57-65, entirely incorporated by reference), as well as any undiscovered
human FcγRs or FcγR isoforms or allotypes. An FcγR may be from any organism,
including but not limited to humans, mice, rats, rabbits, and monkeys. Mouse
FcγRs include but are not limited to FcγRI (CD64), FcγRII (CD32), FcγRIII
(CD16), and FcγRIII-2 (CD16-2), as well as any undiscovered mouse FcγRs or
FcγR isoforms or allotypes.
By “FcRn” or “neonatal Fc Receptor” as used herein is meant a protein that binds
the IgG antibody Fc region and is encoded at least in part by an FcRn gene. The
FcRn may be from any organism, including but not limited to humans, mice, rats,
rabbits, and monkeys. As is known in the art, the functional FcRn protein
comprises two polypeptides, often referred to as the heavy chain and light chain.
The light chain is betamicroglobulin and the heavy chain is encoded by the
FcRn gene. Unless other wise noted herein, FcRn or an FcRn protein refers to the
complex of FcRn heavy chain with betamicroglobulin.
By “wildtype or parent polypeptide” as used herein is meant an unmodified
polypeptide that is subsequently modified to generate a variant. The wildtype
polypeptide may be a naturally occurring polypeptide, or a variant or engineered
version of a naturally occurring polypeptide. Wildtype polypeptide may refer to the
polypeptide itself, compositions that comprise the parent polypeptide, or the amino
acid sequence that encodes it. Accordingly, by “wildtype immunoglobulin” as used
herein is meant an unmodified immunoglobulin polypeptide that is modified to
generate a variant, and by “wildtype antibody” as used herein is meant an
unmodified antibody that is modified to generate a variant antibody. It should be
noted that “wildtype antibody” includes known commercial, recombinantly
produced antibodies as outlined below.
The term “fragment crystallizable (Fc) polypeptide” is the portion of an antibody
molecule that interacts with effector molecules and cells. It comprises the C-
terminal portions of the immunoglobulin heavy chains.
The term "Framework" or "FR" refers to variable domain residues other than
hypervariable region (HVR) residues. The FR of a variable domain generally
consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and
FR sequences generally appear in the following sequence in VH (or VL): FR1-
H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
The terms “full length antibody,” “intact antibody,” and “whole antibody” are used
herein interchangeably to refer to an antibody having a structure substantially
similar to a native antibody structure or having heavy chains that contain an Fc
region as defined herein.
A “functional Fc region” possesses an “effector function” of a native sequence Fc
region. Exemplary “effector functions” include C1q binding; complement
dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated
cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g.
B cell receptor; BCR), etc. Such effector functions generally require the Fc region
to be combined with a binding domain (e.g. an antibody variable domain) and can
be assessed using various assays as herein disclosed, for example.
“Hinge region” is generally defined as stretching from Glu216 to Pro230 of human
IgG1 (Burton, Molec. Immunol. 22 (1985) 161-206). Hinge regions of other IgG
isotypes may be aligned with the IgG1 sequence by placing the first and last
cysteine residues forming inter-heavy chain S—S bonds in the same positions.
The “lower hinge region” of an Fc region is normally defined as the stretch of
residues immediately C-terminal to the hinge region, i.e. residues 233 to 239 of the
Fc region.
“Homology” is defined as the percentage of residues in the amino acid sequence
variant that are identical after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent homology. Methods and computer
programs for the alignment are well known in the art. One such computer program
is “Align 2”, authored by Genentech, Inc., which was filed with user
documentation in the United States Copyright Office, Washington, D.C. 20559, on
Dec. 10, 1991.
The terms "host cell," "host cell line," and "host cell culture" are used
interchangeably and refer to cells into which exogenous nucleic acid has been
introduced, including the progeny of such cells. Host cells include "transformants"
and "transformed cells," which include the primary transformed cell and progeny
derived there from without regard to the number of passages. Progeny may not be
completely identical in nucleic acid content to a parent cell, but may contain
mutations. Mutant progeny that have the same function or biological activity as
screened or selected for in the originally transformed cell are included herein.
A “human antibody” is one which possesses an amino acid sequence which
corresponds to that of an antibody produced by a human or a human cell or derived
from a non-human source that utilizes human antibody repertoires or other human
antibody-encoding sequences. This definition of a human antibody specifically
excludes a humanized antibody comprising non-human antigen-binding residues.
“Human effector cells” are leukocytes which express one or more FcRs and
perform effector functions. Preferably, the cells express at least FcγRIII and
perform ADCC effector function. Examples of human leukocytes which mediate
ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK)
cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells
being preferred. The effector cells may be isolated from a native source thereof,
e.g. from blood or PBMCs as described herein.
A “humanized” antibody refers to a chimeric antibody comprising amino acid
residues from non-human HVRs and amino acid residues from human FRs. In
certain embodiments, a humanized antibody will comprise substantially all of at
least one, and typically two, variable domains, in which all or substantially all of
the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or
substantially all of the FRs correspond to those of a human antibody. A humanized
antibody optionally may comprise at least a portion of an antibody constant region
derived from a human antibody. A “humanized form” of an antibody, e.g., a non-
human antibody, refers to an antibody that has undergone humanization.
The term “hypervariable region” or “HVR,” as used herein, refers to each of the
regions of an antibody variable domain which are hypervariable in sequence and/or
form structurally defined loops (“hypervariable loops”). Generally, native four-
chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in
the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the
hypervariable loops and/or from the “complementarity determining regions”
(CDRs), the latter being of highest sequence variability and/or involved in antigen
recognition. Exemplary hypervariable loops occur at amino acid residues 26-32
(L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia,
and Lesk, J. Mol. Biol. 196 (1987) 901-917). Exemplary CDRs (CDR-L1, CDR-
L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-
34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3
(Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, MD (1991)). With the
exception of CDR1 in VH, CDRs generally comprise the amino acid residues that
form the hypervariable loops. CDRs also comprise “specificity determining
residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained
within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-
CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-
H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of
H1, 50-58 of H2, and 95-102 of H3 (See Almagro, and Fransson, Front. Biosci. 13
(2008) 1619-1633). Unless otherwise indicated, HVR residues and other residues
in the variable domain (e.g., FR residues) are numbered herein according to Kabat
et al., supra.
“Immune complex” refers to the relatively stable structure which forms when at
least one target molecule and at least one heterologous Fc region-containing
polypeptide bind to one another forming a larger molecular weight complex.
Examples of immune complexes are antigen-antibody aggregates and target
molecule-immunoadhesin aggregates. The term “immune complex” as used herein,
unless indicated otherwise, refers to an ex vivo complex (i.e. other than the form or
setting in which it may be found in nature). However, the immune complex may be
administered to a mammal, e.g. to evaluate clearance of the immune complex in the
mammal.
An “immunoconjugate” is an antibody conjugated to one or more heterologous
molecule(s), including but not limited to a cytotoxic agent.
An “individual” or “subject” is a mammal. Mammals include, but are not limited
to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g.,
humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice
and rats). In certain embodiments, the individual or subject is a human.
An "isolated" antibody is one which has been separated from a component of its
natural environment. In some embodiments, an antibody is purified to greater than
95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-
PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic
(e.g., ion exchange or reverse phase HPLC). For review of methods for assessment
of antibody purity, see, e.g., Flatman, et al., J. Chromatogr. B 848 (2007) 79-87.
An “isolated” polypeptide is one that has been identified and separated and/or
recovered from a component of its natural environment. Contaminant components
of its natural environment are materials that would interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes, hormones, and
other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the
polypeptide will be purified (1) to greater than 95% by weight of polypeptide as
determined by the Lowry method, and most preferably more than 99% by weight,
(2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal
amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by
SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or,
preferably, silver stain. Isolated polypeptide includes the polypeptide in situ within
recombinant cells since at least one component of the polypeptide's natural
environment will not be present. Ordinarily, however, isolated polypeptide will be
prepared by at least one purification step.
An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated
from a component of its natural environment. An isolated nucleic acid includes a
nucleic acid molecule contained in cells that ordinarily contain the nucleic acid
molecule, but the nucleic acid molecule is present extrachromosomally or at a
chromosomal location that is different from its natural chromosomal location.
“Isolated nucleic acid encoding an antibody refers to one or more nucleic acid
molecules encoding antibody heavy and light chains (or fragments thereof),
including such nucleic acid molecule(s) in a single vector or separate vectors, and
such nucleic acid molecule(s) present at one or more locations in a host cell.
The word “label” when used herein refers to a detectable compound or composition
which is conjugated directly or indirectly to the polypeptide. The label may be
itself be detectable (e.g., radioisotope labels or fluorescent labels) or, in the case of
an enzymatic label, may catalyze chemical alteration of a substrate compound or
composition which is detectable.
The term “ligand binding domain” as used herein refers to any native cell-surface
receptor or any region or derivative thereof retaining at least a qualitative ligand
binding ability of a corresponding native receptor. In a specific embodiment, the
receptor is from a cell-surface polypeptide having an extracellular domain that is
homologous to a member of the immunoglobulin supergenefamily. Other receptors,
which are not members of the immunoglobulin supergenefamily but are
nonetheless specifically covered by this definition, are receptors for cytokines, and
in particular receptors with tyrosine kinase activity (receptor tyrosine kinases),
members of the hematopoietin and nerve growth factor receptor superfamilies, and
cell adhesion molecules, e.g. (E-, L- and P-) selectins.
The term "monoclonal antibody" as used herein refers to an antibody obtained from
a population of substantially homogeneous antibodies, i.e., the individual
antibodies comprising the population are identical and/or bind the same epitope,
except for possible variant antibodies, e.g., containing naturally occurring
mutations or arising during production of a monoclonal antibody preparation, such
variants generally being present in minor amounts. In contrast to polyclonal
antibody preparations, which typically include different antibodies directed against
different determinants (epitopes), each monoclonal antibody of a monoclonal
antibody preparation is directed against a single determinant on an antigen. Thus,
the modifier “monoclonal” indicates the character of the antibody as being obtained
from a substantially homogeneous population of antibodies, and is not to be
construed as requiring production of the antibody by any particular method. For
example, the monoclonal antibodies to be used in accordance with the present
invention may be made by a variety of techniques, including but not limited to the
hybridoma method, recombinant DNA methods, phage-display methods, and
methods utilizing transgenic animals containing all or part of the human
immunoglobulin loci, such methods and other exemplary methods for making
monoclonal antibodies being described herein.
A “naked antibody” refers to an antibody that is not conjugated to a heterologous
moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present
in a pharmaceutical formulation.
"Native antibodies" refer to naturally occurring immunoglobulin molecules with
varying structures. For example, native IgG antibodies are heterotetrameric
glycoproteins of about 150,000 daltons, composed of two identical light chains and
two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each
heavy chain has a variable region (VH), also called a variable heavy domain or a
heavy chain variable domain, followed by three constant domains (CH1, CH2, and
CH3). Similarly, from N- to C-terminus, each light chain has a variable region
(VL), also called a variable light domain or a light chain variable domain, followed
by a constant light (CL) domain. The light chain of an antibody may be assigned to
one of two types, called kappa (κ) and lambda (λ), based on the amino acid
sequence of its constant and variable domain.
A “native sequence Fc region” comprises an amino acid sequence identical to the
amino acid sequence of an Fc region found in nature. Native sequence human Fc
regions include a native sequence human IgG1 Fc region (non-A and A allotypes);
native sequence human IgG2 Fc region; native sequence human IgG3 Fc region;
and native sequence human IgG4 Fc region as well as naturally occurring variants
thereof.
Nucleic acid is “operably linked” when it is placed into a functional relationship
with another nucleic acid sequence. For example, DNA for a presequence or
secretory leader is operably linked to DNA for a polypeptide if it is expressed as a
preprotein that participates in the secretion of the polypeptide; a promoter or
enhancer is operably linked to a coding sequence if it affects the transcription of
the sequence; or a ribosome binding site is operably linked to a coding sequence if
it is positioned so as to facilitate translation. Generally, “operably linked” means
that the DNA sequences being linked are contiguous, and, in the case of a secretory
leader, contiguous and in reading phase. However, enhancers do not have to be
contiguous. Linking is accomplished by ligation at convenient restriction sites. If
such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in
accordance with conventional practice.
The term “package insert” is used to refer to instructions customarily included in
commercial packages of therapeutic products, that contain information about the
indications, usage, dosage, administration, combination therapy, contraindications
and/or warnings concerning the use of such therapeutic products.
By “position” as used herein is meant a location in the sequence of a protein.
Positions may be numbered sequentially, or according to an established format, for
example the EU index for antibody numbering.
The terms “polypeptide” and “protein” are used interchangeably to refer to a
polymer of amino acid residues, comprising natural or non-natural amino acid
residues, and are not limited to a minimum length.
Thus, peptides, oligopeptides, dimers, multimers, and the like are included within
the definition. Both full-length proteins and fragments thereof are encompassed by
the definition. The terms also include post-translational modifications of the
polypeptide, including, for example, glycosylation, sialylation, acetylation, and
phosphorylation.
Furthermore, a “polypeptide” herein also refers to a modified protein such as single
or multiple amino acid residue deletions, additions, and substitutions to the native
sequence, as long as the protein maintains a desired activity. For example, a serine
residue may be substituted to eliminate a single reactive cysteine or to remove
disulfide bonding or a conservative amino acid substitution may be made to
eliminate a cleavage site. These modifications may be deliberate, as through site-
directed mutagenesis, or may be accidental, such as through mutations of hosts
which produce the proteins or errors due to polymerase chain reaction (PCR)
amplification.
The term “wildtype polypeptide” and “wildtype (human) Fc region” as used herein
refers to a polypeptide and Fc region, respectively, comprising an amino acid
sequence which lacks one or more of the Fc region modifications disclosed herein,
because they have not been introduced, and serve for example as controls. The
wildtype polypeptide may comprise a native sequence Fc region or an Fc region
with pre-existing amino acid sequence modifications (such as additions, deletions
and/or substitutions).
The term "pharmaceutical formulation" refers to a preparation which is in such
form as to permit the biological activity of an active ingredient contained therein to
be effective, and which contains no additional components which are unacceptably
toxic to a subject to which the formulation would be administered.
A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical
formulation, other than an active ingredient, which is nontoxic to a subject., A
pharmaceutically acceptable carrier includes, but is not limited to, a buffer,
excipient, stabilizer, or preservative.
A polypeptide with “altered” FcR binding affinity or ADCC activity is one which
has either enhanced or diminished FcR binding activity and/or ADCC activity
compared to a parent polypeptide or to a polypeptide comprising a native sequence
Fc region. The polypeptide variant which “displays increased binding” to an FcR
binds at least one FcR with better affinity than the parent polypeptide. The
polypeptide variant which “displays decreased binding” to an FcR, binds at least
one FcR with worse affinity than a parent polypeptide. Such variants which display
decreased binding to an FcR may possess little or no appreciable binding to an
FcR, e.g., 0-20% binding to the FcR compared to a native sequence IgG Fc region,
e.g. as determined in the Examples herein.
The polypeptide which binds an FcR with “reduced affinity” than a parent
polypeptide, is one which binds any one or more of the above identified FcRs with
substantially reduced binding affinity than the parent antibody, when the amounts
of polypeptide variant and parent polypeptide in the binding assay are essentially
the same. For example, the polypeptide variant with reduced FcR binding affinity
may display from about 1.15 fold to about 100 fold, e.g. from about 1.2 fold to
about 50 fold reduction in FcR binding affinity compared to the parent polypeptide,
where FcR binding affinity is determined, for example, as disclosed in the
Examples herein.
The polypeptide comprising an Fc variant which “mediates antibody-dependent
cell-mediated cytotoxicity (ADCC) in the presence of human effector cells less
effectively” than a parent or wildtype polypeptide is one which in vitro or in vivo is
substantially less effective at mediating ADCC, when the amounts of polypeptide
variant and parent antibody used in the assay are essentially the same. Generally,
such variants will be identified using the in vitro ADCC assay as herein disclosed,
but other assays or methods for determining ADCC activity, e.g. in an animal
model etc, are contemplated. The preferred variant is from about 1.5 fold to about
100 fold, e.g. from about two fold to about fifty fold, less effective at mediating
ADCC than the parent, e.g. in the in vitro assay disclosed herein.
A “receptor” is a polypeptide capable of binding at least one ligand. The preferred
receptor is a cell-surface receptor having an extracellular ligand-binding domain
and, optionally, other domains (e.g. transmembrane domain, intracellular domain
and/or membrane anchor). The receptor to be evaluated in the assay described
herein may be an intact receptor or a fragment or derivative thereof (e.g. a fusion
protein comprising the binding domain of the receptor fused to one or more
heterologous polypeptides). Moreover, the receptor to be evaluated for its binding
properties may be present in a cell or isolated and optionally coated on an assay
plate or some other solid phase.
The term “receptor binding domain” is used to designate any native ligand for a
receptor, including cell adhesion molecules, or any region or derivative of such
native ligand retaining at least a qualitative receptor binding ability of a
corresponding native ligand. This definition, among others, specifically includes
binding sequences from ligands for the above-mentioned receptors.
As used herein, “treatment” (and grammatical variations thereof such as “treat” or
“treating”) refers to clinical intervention in an attempt to alter the natural course of
the individual being treated, and can be performed either for prophylaxis or during
the course of clinical pathology. Desirable effects of treatment include, but are not
limited to, preventing occurrence or recurrence of disease, alleviation of symptoms,
diminishment of any direct or indirect pathological consequences of the disease,
preventing metastasis, decreasing the rate of disease progression, amelioration or
palliation of the disease state, and remission or improved prognosis. In some
embodiments, antibodies of the invention are used to delay development of a
disease or to slow the progression of a disease.
By “variant protein” or “protein variant”, or “variant” as used herein is meant a
protein that differs from that of a parent protein by virtue of at least one amino acid
modification. Protein variant may refer to the protein itself, a composition
comprising the protein, or the amino sequence that encodes it. Preferably, the
protein variant has at least one amino acid modification compared to the parent
protein, e.g. from about one to about seventy amino acid modifications, and
preferably from about one to about five amino acid modifications compared to the
parent. The protein variant sequence herein will preferably possess at least about
80% homology with a parent protein sequence, and most preferably at least about
90% homology, more preferably at least about 95% homology. Variant protein can
refer to the variant protein itself, compositions comprising the protein variant, or
the DNA sequence that encodes it. Accordingly, by “antibody variant” or “variant
antibody” as used herein is meant an antibody that differs from a parent antibody
by virtue of at least one amino acid modification, “IgG variant” or “variant IgG” as
used herein is meant an antibody that differs from a parent IgG by virtue of at least
one amino acid modification, and “immunoglobulin variant” or “variant
immunoglobulin” as used herein is meant an immunoglobulin sequence that differs
from that of a parent immunoglobulin sequence by virtue of at least one amino acid
modification.
The term “variable region” or “variable domain” refers to the domain of an
antibody heavy or light chain that is involved in binding the antibody to antigen.
The variable domains of the heavy chain and light chain (VH and VL, respectively)
of a native antibody generally have similar structures, with each domain
comprising four conserved framework regions (FRs) and three hypervariable
regions (HVRs). (See, e.g., Kindt, et al., Kuby Immunology, 6th ed., W.H.
Freeman and Co. (2007) page 91). A single VH or VL domain may be sufficient to
confer antigen-binding specificity. Furthermore, antibodies that bind a particular
antigen may be isolated using a VH or VL domain from an antibody that binds the
antigen to screen a library of complementary VL or VH domains, respectively. See,
e.g., Portolano, et al., J. Immunol. 150 (1993) 880-887; Clackson, et al., Nature 352
(1991) 624-628.
The term "vector," as used herein, refers to a nucleic acid molecule capable of
propagating another nucleic acid to which it is linked. The term includes the vector
as a self-replicating nucleic acid structure as well as the vector incorporated into
the genome of a host cell into which it has been introduced. Certain vectors are
capable of directing the expression of nucleic acids to which they are operatively
linked. Such vectors are referred to herein as "expression vectors."
The present application is directed to polypeptides that include amino acid
modifications that modulate binding to Fc receptors, in particularly to Fcγ
receptors.
Detailed Description
The invention herein relates to a method for making a polypeptide comprising a Fc
variant. The “parent”, “starting” , “nonvariant” or wildtype polypeptide is prepared
using techniques available in the art for generating polypeptides or antibodies
comprising an Fc region. In the preferred embodiment of the invention, the parent
polypeptide is an antibody and exemplary methods for generating antibodies are
described in more detail in the following sections. The parent polypeptide may,
however, be any other polypeptide comprising an Fc region, e.g. an
immunoadhesin. Methods for making immunoadhesins are elaborated in more
detail herein below.
In an alternative embodiment, a variant Fc region (Fc variant) may be generated
according to the methods herein disclosed and this Fc variant can be fused to a
heterologous polypeptide of choice, such as an antibody variable domain or
binding domain of a receptor or ligand.
The wildtype polypeptide comprises an Fc region. Generally the Fc region of the
wildtype polypeptide will comprise a native or wildtype sequence Fc region, and
preferably a human native sequence Fc region (human Fc region). However, the Fc
region of the wildtype polypeptide may have one or more pre-existing amino acid
sequence alterations or modifications from a native sequence Fc region. For
example, the C1q or Fcγ binding activity of the Fc region may have been
previously altered (other types of Fc region modifications are described in more
detail below). In a further embodiment the parent polypeptide Fc region is
“conceptual” and, while it does not physically exist, the antibody engineer may
decide upon a desired variant Fc region amino acid sequence and generate a
polypeptide comprising that sequence or a DNA encoding the desired variant Fc
region amino acid sequence.
In the preferred embodiment of the invention, however, a nucleic acid encoding an
Fc region of a wildtype polypeptide is available and this nucleic acid sequence is
altered to generate a variant nucleic acid sequence encoding the Fc region variant.
DNA encoding an amino acid sequence variant of the starting polypeptide is
prepared by a variety of methods known in the art. These methods include, but are
not limited to, preparation by site-directed (or oligonucleotide-mediated)
mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared
DNA encoding the polypeptide
Site-directed mutagenesis is a preferred method for preparing substitution variants.
This technique is well known in the art (see, e.g., Carter, et al., Nucleic Acids Res.
13 (1985) 4431-4443 and Kunkel, et al., Proc. Natl. Acad. Sci. USA 82 (1985)
488). Briefly, in carrying out site-directed mutagenesis of DNA, the starting DNA
is altered by first hybridizing an oligonucleotide encoding the desired mutation to a
single strand of such starting DNA. After hybridization, a DNA polymerase is used
to synthesize an entire second strand, using the hybridized oligonucleotide as a
primer, and using the single strand of the starting DNA as a template. Thus, the
oligonucleotide encoding the desired mutation is incorporated in the resulting
double-stranded DNA.
PCR mutagenesis is also suitable for making amino acid sequence variants of the
starting polypeptide. See Higuchi, in PCR Protocols, Academic Press (1990) pp.
177-183; and Vallette, et al., Nuc. Acids Res. 17 (1989) 723-733. Briefly, when
small amounts of template DNA are used as starting material in a PCR, primers
that differ slightly in sequence from the corresponding region in a template DNA
can be used to generate relatively large quantities of a specific DNA fragment that
differs from the template sequence only at the positions where the primers differ
from the template.
Another method for preparing variants, cassette mutagenesis, is based on the
technique described by Wells, et al., Gene 34 (1985) 315-323.
One embodiment of the invention encompasses polypeptides comprising an Fc
region of an antibody, comprising the addition, substitution, or deletion of at least
one amino acid residue to the Fc region resulting in reduced or ablated affinity for
at least one Fc receptor. The Fc region interacts with a number of receptors or
ligands including but not limited to Fc Receptors (e.g., FcγRI, FcγRIIA, FcγRIIIA),
the complement protein CIq, and other molecules such as proteins A and G. These
interactions are essential for a variety of effector functions and downstream
signaling events including, but not limited to, antibody dependent cell-mediated
cytotoxicity (ADCC), Antibody-dependent cellular phagocytosis (ADCP) and
complement dependent cytotoxicity (CDC). Accordingly, in certain embodiments
the variants of the invention have reduced or ablated affinity for an Fc receptor
responsible for an effector function compared to a polypeptide having the same
amino acid sequence as the polypeptide comprising a Fc variant of the invention
but not comprising the addition, substitution, or deletion of at least one amino acid
residue to the Fc region (also referred to herein as an "wildtype polypeptide"). In
certain embodiments, polypeptide comprising a Fc variant of the invention
comprise at least one or more of the following properties: reduced or ablated
effector (ADCC and/or CDC and/or ADCP) function, reduced or ablated binding to
Fc receptors, reduced or ablated binding to C1q or reduced or ablated toxicities.
More specifically, embodiments of the invention provide anti-CD20 (same as
GA101 or GA), anti-CD9 (same as TA) and anti-Selectin (pSel) antibodies with
reduced affinity for Fc receptors (e.g. FcγRI, FcγRII, FcγRIIIA) and/or the
complement protein C1q.
In one embodiment, antibodies of the invention comprise an Fc region comprising
at least one addition, substitution, or deletion of an amino acid residue at position
P329, wherein the numbering system of the constant region is that of the EU index
as set forth in Kabat, et al., NIH Publication 91 (1991) 3242, National Technical
Information Service, Springfield, VA.
In a specific embodiment, polypeptides of the invention comprise an Fc variant of a
wild-type human Fc polypeptide said variant comprising an amino acid substitution
at position Pro329, where the numbering of the residues in the IgG Fc region is that
of the EU index as in Kabat. In still another embodiment, said variant comprises at
least one further amino acid substitution.
In still another embodiment the polypeptide comprising a Fc variant of a wild-type
human Fc polypeptide has an amino acid substitution, deletion or addition which
destroys or diminishes the function of the proline sandwich in the region and/or
interface of the Fc polypeptide with the Fc Gamma receptor.
In another embodiment Pro329 is substituted with an amino acid which is either
smaller or larger then proline. In still another embodiment the substituted amino
acid is Gly, Ala or Arg. In a further aspect of the invention Pro329 of the Fc
polypeptide is substituted with glycine.
In still another embodiment said polypeptide comprising a Fc variant has at least
one further amino acid substitution, addition of deletion. In still another
embodiment, said variants exhibit a reduced affinity to a human Fc receptor (FcγR)
and/or a human complement receptor as compared to the polypeptide comprising
the wildtype Fc polypeptide.
In another embodiment said polypeptide comprising a Fc variant exhibits a reduced
affinity to a human Fc receptor (FcγR) and/or a human complement receptor as
compared to the polypeptide comprising the wildtype human Fc region. In a further
embodiment the affinity to at least one of the FcγRI, FcγRII, FcγRIIIA is reduced,
in a still further embodiment the affinity to the FcγRI and FcγRIIIA is reduced, and
in a still further embodiment the affinity to the FcγRI, FcγRII and FcγRIIIA is
reduced, in still a further aspect of the invention the affinity to the FcγRI receptor,
FcγRIIIA receptor and C1q is reduced, and in still a further aspect of the invention
the affinity to the FcγRI, FcγRII, FcγRIIIA and C1q receptor is reduced.
In still a further embodiment the ADCC induced by said polypeptide comprising a
Fc variant is reduced and in a preferred embodiment the ADCC is reduced to at
least 20% of the ADCC induced by the polypeptide comprising the wildtype Fc
polypeptide. In still a further aspect of the invention, the ADCC and CDC induced
by the polypeptide comprising the wildtype Fc polypeptide is decreased or ablated
and in a still further aspect the polypeptide comprising a Fc variant described above
exhibit a decreased ADCC, CDC and ADCP compared to the polypeptide
comprising the wildtype Fc polypeptide.
In one embodiment the at least one further amino acid substitution in the
polypeptide comprising the Fc variant is selected from the group: S228P, E233P,
L234A, L235A, L235E, N297A, N297D, or P331S.
In a certain aspect of the invention the polypeptide comprising a Fc variant
comprises an antibody. In still another aspect of the invention the polypeptide
comprising a Fc variant comprises a human IgG1 or IgG4 Fc region. In still a
further aspect of the invention the variants are IgG1 or IgG4 antibodies.
In another embodiment of the invention, polypeptides comprising a Pro329 Fc
variant variants further comprise at least one addition, substitution, or deletion of
an amino acid residue in the Fc region that is correlated with increased stability of
the antibody. In still a further aspect of the invention the affinity of the polypeptide
comprising a Fc variant described above to the Fcn receptor is only slightly, and for
example not more than 10-20% of the affinity of polypeptide comprising the
wildtype Fc polypeptide altered.
In one embodiment, the addition, substitution, or deletion of an amino acid residue
in a polypeptide comprising a Fc variant is at position 228 and/or 235 of the Fc
region, wherein the numbering system of the constant region is that of the EU
index as set forth in Kabat, et al.
In a specific embodiment serine at position 228 and/or leucine at position 235 in
said polypeptide comprising a Fc variant is substituted by another amino acid.
In a specific embodiment, polypeptides comprising a Fc variant of the invention
comprise an Fc region comprising an amino acid substitution at position 228,
wherein the serine residue is substituted with proline.
In a specific embodiment, polypeptides comprising a Fc variant of the invention
comprise an Fc region comprising an amino acid substitution at position 235,
wherein the leucine residue is substituted with glutamic acid.
In a specific embodiment the polypeptide comprising a Fc variant comprises a
triple mutation: an amino acid substitution at position P329, a S228P and a L235E
mutation (P329 / SPLE).
In a further specific embodiment the polypeptide comprising a Fc variant
comprises a human IgG4 region.
In one embodiment, the addition, substitution, or deletion of an amino acid residue
is at position 234 and/or 235 of the Fc region, wherein the numbering system of the
constant region is that of the EU index as set forth in Kabat et al..
In a specific embodiment leucine at position 234 and/or leucine at position 235 in
the polypeptide comprising a Fc variant is substituted by another amino acid.
In a specific embodiment, polypeptides comprising a Fc variant of the invention
comprise an Fc region comprising an amino acid substitution at position 234,
wherein the leucine residue is substituted with alanine.
In a specific embodiment, polypeptides comprising a Fc variant of the invention
comprise an Fc region comprising an amino acid substitution at position 235,
wherein the leucine residue is substituted with serine.
In a specific embodiment the polypeptide comprising an Fc variant of a wildtype
human Fc polypeptide comprises a triple mutation: an amino acid substitution at
position Pro329, a L234A and a L235A mutation (P329 / LALA).
In a further specific embodiment the above mentioned polypeptides comprise a
human IgG1 region.
While it is preferred to alter binding to a FcγR, Fc region variants with altered
binding affinity for the neonatal receptor (FcRn) are also contemplated herein. Fc
region variants with improved affinity for FcRn are anticipated to have longer
serum half-lives, and such molecules will have useful applications in methods of
treating mammals where long half-life of the administered polypeptide is desired,
e.g., to treat a chronic disease or disorder. Fc region variants with decreased FcRn
binding affinity, on the contrary, are expected to have shorter half-lives, and such
molecules may, for example, be administered to a mammal where a shortened
circulation time may be advantageous, e.g. for in vivo diagnostic imaging or for
polypeptides which have toxic side effects when left circulating in the blood stream
for extended periods, etc. Fc region variants with decreased FcRn binding affinity
are anticipated to be less likely to cross the placenta, and thus may be utilized in the
treatment of diseases or disorders in pregnant women.
Fc region variants with altered binding affinity for FcRn include those comprising
an Fc region amino acid modification at any one or more of amino acid positions
238, 252, 253, 254, 255, 256, 265, 272, 286, 288, 303, 305, 307, 309, 311, 312,
317, 340, 356, 360, 362, 376, 378, 380, 382, 386, 388, 400, 413, 415, 424, 433,
434, 435, 436, 439 or 447. Those which display reduced binding to FcRn will
generally comprise an Fc region amino acid modification at any one or more of
amino acid positions 252, 253, 254, 255, 288, 309, 386, 388, 400, 415, 433, 435,
436, 439 or 447; and those with increased binding to FcRn will usually comprise an
Fc region amino acid modification at any one or more of amino acid positions 238,
256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378,
380, 382, 413, 424 or 434.
In another embodiment, antibodies of the invention may be any of any class (for
example, but not limited to IgG, IgM, and IgE). In certain embodiments, antibodies
of the invention are members of the IgG class of antibodies. In a specific
embodiment, antibodies of the invention are of the IgGl, IgG2 or IgG4 subclass. In
another specific embodiment, antibodies of the invention are of the IgGl subclass
and comprise the following amino acid substitutions: P329G and/or L234A and
L235A of the Fc region. In alternate embodiments, antibodies of the invention are
of the IgG4 subclass. In a specific embodiment, antibodies of the invention are of
the IgG4 subclass and comprise the following amino acid substitutions: P329G
and/or S228P and L235E of the Fc region. In certain embodiments, the modified
antibodies of the present invention may be produced by combining a variable
domain, or fragment thereof, with an Fc domain comprising one or more of the
amino acid substitutions disclosed herein. In other embodiments modified
antibodies of the invention may be produced by modifying an Fc domain-
containing antibody by introducing one or more of the amino acid substitutions
residues into the Fc domain.
Reduced binding to Fc ligands
One skilled in the art will understand that antibodies of the invention may have
altered (relative to an unmodified antibody) FcγR and/or C1q binding properties
(examples of binding properties include but are not limited to, binding specificity,
equilibrium dissociation constant (K ), dissociation and association rates (k and
D off
k , respectively) binding affinity and/or avidity) and that certain alterations are
more or less desirable. It is known in the art that the equilibrium dissociation
constant (K ) is defined as k /k . One skilled in the art can determine which
D off on
kinetic parameter is most important for a given antibody application. For example,
a modification that reduces binding to one or more positive regulator (e.g.,
FcγRIIIA) and/or enhanced binding to an inhibitory Fc receptor (e.g., FcγRIIB)
would be suitable for reducing ADCC activity. Accordingly, the ratio of binding
affinities (e.g., equilibrium dissociation constants (K )) can indicate if the ADCC
activity of an antibody of the invention is enhanced or decreased. Additionally, a
modification that reduces binding to C1q would be suitable for reducing or
eliminating CDC activity. The affinities and binding properties of an Fc region for
its ligand, may be determined by a variety of in vitro assay methods (biochemical
or immunological based assays) known in the art for determining Fc-FcγR
interactions, i.e., specific binding of an Fc region to an FcγR including but not
limited to, equilibrium methods (e.g., enzyme-linked immuno absorbent assay
(ELISA) or radioimmunoassay (RIA)), or kinetics (e.g., BIACORE analysis), and
other methods such as indirect binding assays, competitive inhibition assays,
fluorescence resonance energy transfer (FRET), gel electrophoresis and
chromatography (e.g., gel filtration). These and other methods may utilize a label
on one or more of the components being examined and/or employ a variety of
detection methods including but not limited to chromogenic, fluorescent,
luminescent, or isotopic labels. A detailed description of binding affinities and
kinetics can be found in Paul, W.E., ed., Fundamental Immunology, 4 Ed.,
Lippincott-Raven, Philadelphia (1999).
In one aspect of the invention a polypeptide comprising an Fc variant of a wild-
type human Fc region, said variant comprising an amino acid substitution at
position Pro329 and at least one further amino acid substitution, exhibits a reduced
affinity to a human Fc receptor (FcγR) and/or a human complement receptor as
compared to the polypeptide comprising the wildtype Fc polypeptide. In one aspect
polypeptides comprising an Fc variant of the invention exhibit affinities for a Fc
receptor that is at least 2 fold, or at least 3 fold, or at least 5 fold, or at least 7 fold,
or a least 10 fold, or at least 20 fold, or at least 30 fold, or at least 40 fold, or at
least 50 fold, or at least 60 fold, or at least 70 fold, or at least 80 fold, or at least 90
fold, or at least 100 fold, or at least 200 fold less than for a wildtype Fc
polypeptide.
In one aspect polypeptides comprising an Fc variant of the invention exhibit
reduced binding affinity for one or more Fc receptors including, but not limited to
FcγRI (CD64) including isoforms FcγRIA, FcγRII and FcγRIII (CD 16, including
isoforms FcγRIIIA) as compared to an unmodified antibody.
In one aspect polypeptides comprising an Fc variant of the invention exhibit
reduced binding affinity for FcγRI (CD64) FcγRIIA and FcγRIIIA as compared to
an unmodified antibody.
In one aspect polypeptides comprising an Fc variant of the invention exhibit
reduced binding affinity for FcγRIIA and FcγRIIIA as compared to an unmodified
antibody.
In one aspect polypeptides comprising an Fc variant of the invention exhibit
reduced binding affinity for FcγRI (CD64) and FcγRIIIA as compared to an
unmodified antibody.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibiting a reduced binding affinity for the Fc receptors also exhibit a
reduced affinity to the C1q receptor.
In certain aspect polypeptides comprising an Fc variant of the invention do not
comprise a concomitant increase in binding to the FcγRIIB receptor as compared to
a wildtype polypeptide. In certain aspects of the invention the polypeptides
comprising an Fc variant have a reduced affinity to the human receptor FcγIIIA,
and to at least one further receptor of the group comprising the human receptors
FcγIIA, FcγIIIB, and C1q compared to the polypeptide comprising the wildtype Fc
polypeptide. In further aspects of the invention polypeptides comprising an Fc
variant have a reduced affinity to the human receptor FcγIIIA, and to at two further
receptors of the group comprising the human receptors FcγIIA, FcγIIIB, and C1q
compared to the polypeptide comprising the wildtype Fc polypeptide. In further
aspect of the invention the polypeptides comprising an Fc variant have a reduced
affinity to the human FcγRIA, FcγIIIA, FcγIIA, FcγIIIB, and C1q compared to the
polypeptide comprising the wildtype Fc polypeptide. In still another aspect of the
invention polypeptides comprising an Fc variant have a reduced affinity to the
human receptor FcγRIA, FcγIIIA, FcγIIA, FcγIIIB, and C1q compared to the
polypeptide comprising the wildtype Fc polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit decreased affinities to FcγRI or FcγRIIA relative to an
unmodified antibody. In one aspect of the invention polypeptides comprising an Fc
variant exhibit affinities for FcγRI or FcγRIIA that are at least 2 fold, or at least 3
fold, or at least 5 fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at
least 30 fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70
fold, or at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold
less than that of a wildtype polypeptide. In one aspect of the invention polypeptides
comprising an Fc variant exhibit affinity for the FcγRI or FcγRIIA that are at least
90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least
%, at least 20%, at least 10%, or at least 5% less than a than that of a wildtype
polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit decreased affinity for the FcγRIIIA relative to an unmodified
antibody. In one aspect polypeptides comprising an Fc variant of the invention
exhibit affinities for FcγRIIIA that are at least 2 fold, or at least 3 fold, or at least 5
fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at least 30 fold, or at
least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70 fold, or at least 80
fold, or at least 90 fold, or at least 100 fold, or at least 200 fold less than that of a
wildtype polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit affinities for FcγRIIIA that are at least 90%, at least 80%, at least
70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least
%, or at least 5% less than that of a wildtype polypeptide.
It is understood in the art that the F1-58V allelic variant of the FcγRIIIA has altered
binding characteristics to antibodies. In one embodiment, polypeptides comprising
an Fc variant of the invention bind with decreased affinities to FcγRIIIA receptors
relative to a wildtype polypeptide. In one aspect polypeptides comprising an Fc
variant of the invention exhibit affinities for FcγRIIIA (Fl 58V) that are at least 2
fold, or at least 3 fold, or at least 5 fold, or at least 7 fold, or a least 10 fold, or at
least 20 fold, or at least 30 fold, or at least 40 fold, or at least 50 fold, or at least 60
fold, or at least 70 fold, or at least 80 fold, or at least 90 fold, or at least 100 fold, or
at least 200 fold less than that of a wildtype polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit decreased affinity for the C1q receptor relative to an unmodified
antibody. In one aspect polypeptides comprising an Fc variant of the invention
exhibit affinities for C1q receptor that are at least 2 fold, or at least 3 fold, or at
least 5 fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at least 30
fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70 fold, or
at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold less than
that of a wildtype polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit affinities for C1q that are at least 90%, at least 80%, at least 70%,
at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or
at least 5% less than that of a wildtype polypeptide.
In one aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit affinities for the human FcγRI, FcγRIIA, FcγRIIIA, FcγRIIIA (Fl
58V) or C1q receptors that are at least 90%, at least 80%, at least 70%, at least
60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or at least
5% less than a wildtype polypeptide.
In another aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit affinities for the FcγRI, FcγRIIA, FcγRIIIA, FcγRIIIA (Fl 58V)
and/or C1q receptors, respectively, that are between about 10 nM to 100 nM, 10
nM to 1 µM, 100 nM to about 100 μM, or about 100 nM to about 10 μM, or about
100 nM to about 1 μM, or about 1 nM to about 100 μM, or about 10 nM to about
100 μM, or about 1 μM to about 100 μM, or about 10 μM to about 100 μM. In
certain embodiments, polypeptides comprising an Fc variant of the invention
exhibit affinities for the FcγRI, FcγRIIA, FcγRIIIA, FcγRIIIA (Fl-58V) or C1q
receptors that are greater than 100 nM, 500 nM, 1 μM, greater than 5 μM, greater
than 10 μM, greater than 25 μM, greater than 50 μM, or greater than 100 μM.
In another aspect of the invention polypeptides comprising an Fc variant of the
invention exhibit increased affinities for the FcγRIIB as compared to a wildtype
polypeptide. In another aspect of polypeptides comprising an Fc variant of the
invention exhibit affinities for the FcγRIIB that are unchanged or increased by at
least at least 2 fold, or at least 3 fold, or at least 5 fold, or at least 7 fold, or a least
fold, or at least 20 fold, or at least 30 fold, or at least 40 fold, or at least 50 fold,
or at least 60 fold, or at least 70 fold, or at least 80 fold, or at least 90 fold, or at
least 100 fold, or at least 200 fold than that of an unmodified antibody. In another
aspect polypeptides comprising an Fc variant of the invention exhibit affinities for
the FcγRIIB receptor that are increased by at least 5%, at least 10%, at least 20%,
at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at
least 90%, or at least 95% than a wildtype polypeptide.
In another aspect of the invention variants of the invention exhibit affinities for the
FcγRI, FcγRIIA FcγRIIIA, or FcγRIIIA (Fl 58V) or C1q receptors that are less than
100 μM, less than 50 μM, less than 10 μM, less than 5 μM, less than 2.5 μM, less
than 1 μM, or less than 100 nM, or less than 10 nM.
Reduced Effector Function
In a certain aspects of the invention polypeptides comprising an Fc variant
according to the invention modulate an effector function as compared to the
polypeptide comprising the wildtype Fc polypeptide.
In still another aspect of the invention this modulation is a modulation of ADCC
and/or ADCP and/or CDC. In a further aspect of the invention this modulation is
down-modulation or reduction in effect. In still another aspect of the invention this
is a modulation of ADCC and still in another aspect of the invention this
modulation is a down-modulation of ADCC. In still another aspect this modulation
is a down-modulation of ADCC and CDC, still in another embodiment this is a
down-modulation is ADCC only, in still another embodiment this is a down-
modulation of ADCC and CDC and/or ADCP. In still another aspect of the
invention the polypeptides comprising an Fc variant according to the invention
down-modulate or reduce ADCC / CDC and ADCP.
In a further aspect of the invention the reduction or down-modulation of ADCC or
CDC or ADCP induced by the polypeptide comprising the Fc variant, is a
reduction to 0, 2.5, 5, 10, 20, 50 or 75% of the value observed for induction of
ADCC, or CDC or ADCP, respectively, by the polypeptide comprising the
wildtype Fc region.
In still further aspects of the invention the modulation of ADCC induced by the
polypeptides comprising an Fc variant according to the invention is a decrease in
potency such that the EC50 of said Fc variant is approximately >10-fold reduced
compared to the polypeptide comprising the wildtype Fc polypeptide.
In still another aspect the variant according to the invention is devoid of any
substantial ADCC and/or CDC and/or ADCP in the presence of human effector
cells as compared to the polypeptide comprising the wildtype Fc polypeptide.
In still another aspect of the invention the polypeptides comprising an Fc variant of
the invention exhibit a reduced, for example reduction by at least 20%, or strongly
reduced, for example reduction by at least 50%, effector function, which could be a
reduction in ADCC (down-modulation), CDC and/ or ADCP.
Reduced ADCC activity
In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the
reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor
(FcR) binding assays can be conducted to ensure that the antibody lacks FcγR
binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas
monocytes express FcγRI, RII and RIII. FcR expression on hematopoietic cells is
summarized in Table 3 on page 464 of Ravetch, and Kinet, Annu. Rev. Immunol. 9
(1991) 457-492. Non-limiting examples of in vitro assays to assess ADCC activity
of a molecule of interest is described in U.S. Patent No. 5,500,362 (see, e.g.
Hellstrom, I., et al., Proc. Nat’l Acad. Sci. USA 83 (1986) 7059-7063) and
Hellstrom, I., et al., Proc. Nat’l Acad. Sci. USA 82 (1985) 1499-1502;
US 5,821,337 (see Bruggemann, M., et al., J. Exp. Med. 166 (1987) 1351-1361).
Alternatively, non-radioactive assays methods may be employed (see, for example,
ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology,
Inc. Mountain View, CA; and CytoTox 96 non-radioactive cytotoxicity assay
(Promega, Madison, WI). Useful effector cells for such assays include peripheral
blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or
additionally, ADCC activity of the molecule of interest may be assessed in vivo,
e.g., in a animal model such as that disclosed in Clynes, et al., Proc. Nat’l Acad.
Sci. USA 95 (1998) 652-656. C1q binding assays may also be carried out to
confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See,
e.g., C1q and C3c binding ELISA in and . To
assess complement activation, a CDC assay may be performed (see, for example,
Gazzano-Santoro, et al., J. Immunol. Methods 202 (1996) 163; Cragg, M.S., et al.,
Blood 101 (2003) 1045-1052; and Cragg, M.S., and Glennie, M.J., Blood 103
(2004) 2738-2743). FcRn binding and in vivo clearance/half life determinations can
also be performed using methods known in the art (see, e.g., Petkova, S.B., et al.,
Int’l. Immunol. 18(12) (2006) 1759-1769).
It is contemplated that polypeptides comprising a Fc variant of the invention are
characterized by in vitro functional assays for determining one or more FcγR
mediated effector cell functions. In certain embodiments, antibodies of the
invention have similar binding properties and effector cell functions in in vivo
models (such as those described and disclosed herein) as those in in vitro based
assays. However, the present invention does not exclude variants of the invention
that do not exhibit the desired phenotype in in vitro based assays but do exhibit the
desired phenotype in vivo. In one embodiment, polypeptides comprising a Fc
variant of the invention exhibit decreased ADCC activities as compared to an
unmodified wildtype Fc polypeptides. In another aspect polypeptides comprising
an Fc variant of the invention exhibit ADCC activities that are at least 2 fold, or at
least 3 fold, or at least 5 fold or at least 10 fold or at least 50 fold or at least 100
fold less than that of an unmodified antibody. In still another embodiment,
antibodies of the invention exhibit ADCC activities that are reduced by at least
%, or at least 20%, or by at least 30%, or by at least 40%, or by at least 50%, or
by at least 60%, or by at least 70%, or by at least 80%, or by at least 90%, or by at
least 100 %,relative to an unmodified antibody. In a further aspect of the invention
the reduction or down-modulation of ADCC induced by the polypeptide
comprising the Fc variant, is a reduction to 0, 2.5, 5, 10, 20, 50 or 75% of the value
observed for induction of ADCC, or CDC or ADCP, respectively, by the
polypeptide comprising the wildtype Fc region. In certain embodiments,
polypeptides comprising an Fc variant of the invention have no detectable ADCC
activity. In specific embodiments, the reduction and/or ablation of ADCC activity
may be attributed to the reduced affinity of the polypeptides comprising a Fc
variant of the invention for Fc ligands and/or receptors. In a specific embodiment
of the invention the down-modulation of ADCC is a decrease in potency such that
the EC50 of said polypeptide comprising an Fc variant is approximately 10-fold or
more reduced compared to the wildtype Fc polypeptide.
In still another aspect the polypeptides comprising an Fc variant according to the
invention modulate ADCC and/or CDC and/or ADCP. In a specific aspect the
variants according to the inventions show a reduced CDC and ADCC and/or ADCP
activity.
Reduced CDC activity
The complement activation pathway is initiated by the binding of the first
component of the complement system (C1q) to a molecule, an antibody for
example, complexed with a cognate antigen. To assess complement activation, a
CDC assay, e.g. as described in Gazzano-Santoro, et al, J. Immunol. Methods 202
(1996) 163, may be performed.
The binding properties of the different variants to C1q can be analyzed by an
ELISA sandwich type immunoassay. The antibody concentration at the half
maximum response determines the EC value. This read-out is reported as relative
difference to the reference standard measured on the same plate together with the
coefficient of variation of sample and reference.
In one embodiment, polypeptides comprising an Fc variant according to the
invention exhibit decreased affinities to C1q relative to a wildtype polypeptide. In
another embodiment, of the polypeptides comprising a Fc variant according to the
invention exhibit affinities for C1q receptor that are at least 2 fold, or at least 3
fold, or at least 5 fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at
least 30 fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70
fold, or at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold
less than the wildtype polypeptide.
In another embodiment, polypeptides comprising a Fc variant according to the
invention exhibit affinities for C1q that are at least 90%, at least 80%, at least 70%,
at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or
at least 5% less than that of the wildtype polypeptide. In another embodiment,
variants according to the invention exhibit affinities for C1q that are between about
100 nM to about 100 μM, or about 100 nM to about 10 μM, or about 100 nM to
about 1 μM, or about 1 nM to about 100 μM, or about 10 nM to about 100 μM, or
about 1 μM to about 100 μM, or about 10 μM to about 100 μM. In certain
embodiments, polypeptides comprising an Fc variant of the invention exhibit
affinities for CIq that are greater than 1 μM, greater than 5 μM, greater than 10 μM,
greater than 25 μM, greater than 50 μM, or greater than 100 μM.
In one embodiment polypeptide comprising an Fc variant of the invention exhibit
decreased CDC activities as compared to the wildtype Fc polypeptide In another
embodiment, polypeptide comprising an Fc variant of the invention exhibit CDC
activities that are at least 2 fold, or at least 3 fold, or at least 5 fold or at least 10
fold or at least 50 fold or at least 100 fold less than that of a wildtype polypeptide.
In still another embodiment polypeptide comprising an Fc variant of the invention
exhibit CDC activities that are reduced by at least 10%, or at least 20%, or by at
least 30%, or by at least 40%, or by at least 50%, or by at least 60%, or by at least
70%, or by at least 80%, or by at least 90%, or by at least 100%, or by at least
200%, or by at least 300%, or by at least 400%, or by at least 500% relative to the
wildtype polypeptide. In certain aspects polypeptide comprising an Fc variant of
the invention exhibit no detectable CDC activities. In specific embodiments, the
reduction and/or ablation of CDC activity may be attributed to the reduced affinity
of the polypeptides comprising an Fc variant for Fc ligands and/or receptors.
Reduced antibody related toxicity
It is understood in the art that biological therapies may have adverse toxicity issues
associated with the complex nature of directing the immune system to recognize
and attack unwanted cells and/or targets. When the recognition and/or the targeting
for attack do not take place where the treatment is required, consequences such as
adverse toxicity may occur. For example, antibody staining of non-targeted tissues
may be indicative of potential toxicity issues.
In one aspect, polypeptide comprising an Fc variant of the invention exhibit
reduced staining of non-targeted tissues as compared to the wildtype polypeptide.
In another aspect, the polypeptide comprising an Fc variant of the invention exhibit
reduced staining of non-targeted tissues that are at least 2 fold, or at least 3 fold, or
at least 5 fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at least 30
fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70 fold, or
at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold less than
that of to a wildtype Fc polypeptide . In another embodiment, variants of the
invention exhibit reduced staining of non-targeted tissues that are reduced by at
least 10%, or at least 20%, or by at least 30%, or by at least 40%, or by at least
50%, or by at least 60%, or by at least 70%, or by at least 80%, or by at least 90%,
or by at least 100%, or by at least 200%, or by at least 300%, or by at least 400%,
or by at least 500% relative to the wildtype Fc polypeptide.
In one embodiment, polypeptides comprising an Fc variant of the invention exhibit
a reduced antibody related toxicity as compared to a wildtype polypeptide. In
another embodiment, polypeptide comprising an Fc variant of the invention exhibit
toxicities that are at least 2 fold, or at least 3 fold, or at least 5 fold, or at least 7
fold, or a least 10 fold, or at least 20 fold, or at least 30 fold, or at least 40 fold, or
at least 50 fold, or at least 60 fold, or at least 70 fold, or at least 80 fold, or at least
90 fold, or at least 100 fold, or at least 200 fold less than that of a wildtype
polypeptide. In another aspect, polypeptides comprising an Fc variant of the
invention exhibit toxicities that are reduced by at least 10%, or at least 20%, or by
at least 30%, or by at least 40%, or by at least 50%, or by at least 60%, or by at
least 70%, or by at least 80%, or by at least 90%, or by at least 100%, or by at least
200%, or by at least 300%, or by at least 400%, or by at least 500% relative to the
wildtype polypeptide.
Thrombocyte aggregation
In one aspect of the invention the wildtype polypeptide induces platelet activation
and/or platelet aggregation, and the variants thereof, i.e. polypeptides, comprising
Fc variants, show a decreased or even ablated thrombocyte activation and/or
aggregation. In still another aspect of the invention these wildtype polypeptides are
antibodies targeting a platelet protein. In yet another aspect the antibody is a CD9
antibody. In still another embodiment this CD9 antibody has a mutation at position
P329G and/ or at position L234A / L235A or S228P / L235E (P329G/LALA,
P329G/SPLE). In a further specific embodiment the antibody is characterized by
the SEQ ID NOs: 8-14.
It is understood in the art that biological therapies may have as adverse effect
thrombocyte aggregation. In vitro and in vivo assays could be used for measuring
thrombocyte aggregation. It is assumed that the in vitro assay reflects the in vivo
situation.
In one aspect, polypeptides comprising an Fc variant of the invention exhibit
reduced thrombocyte aggregation in an in vitro assay compared to the wildtype
polypeptide. In another aspect, polypeptides comprising an Fc variant of the
invention exhibit reduced thrombocyte aggregation in an in vitro assay that is at
least 2 fold, or at least 3 fold, or at least 5 fold, or at least 7 fold, or a least 10 fold,
or at least 20 fold, or at least 30 fold, or at least 40 fold, or at least 50 fold, or at
least 60 fold, or at least 70 fold, or at least 80 fold, or at least 90 fold, or at least
100 fold, or at least 200 fold less than that of the wildtype polypeptide. In another
embodiment, polypeptides comprising an Fc variant of the invention exhibit
reduced thrombocyte aggregation in an in vitro assay that is reduced by at least
%, or at least 20%, or by at least 30%, or by at least 40%, or by at least 50%, or
by at least 60%, or by at least 70%, or by at least 80%, or by at least 90%, or by at
least 100%, or by at least 200%, or by at least 300%, or by at least 400%, or by at
least 500% relative to the wildtype polypeptide.
In still another aspect, polypeptides comprising an Fc variant of the inventions
exhibit a reduced in vivo thrombocyte aggregation compared to the wildtype
polypeptide. In another aspect, variants of the invention exhibit reduced
thrombocyte aggregation in an in vivo assay that is at least 2 fold, or at least 3 fold,
or at least 5 fold, or at least 7 fold, or a least 10 fold, or at least 20 fold, or at least
fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70 fold,
or at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold less
than that of the wildtype Fc polypeptide. In another embodiment, polypeptides
comprising an Fc variant of the invention exhibit reduced thrombocyte aggregation
in an in vivo assay that is reduced by at least 10%, or at least 20%, or by at least
%, or by at least 40%, or by at least 50%, or by at least 60%, or by at least 70%,
or by at least 80%, or by at least 90%, or by at least 100%, or by at least 200%, or
by at least 300%, or by at least 400%, or by at least 500% relative to the wildtype
polypeptide.
Internalizing Antibodies
Variants of the invention may bind to cell-surface antigens that may internalize,
further carrying the antibodies into the cell. Once inside the cell, the variants may
be released into the cytoplasm, targeted to a specific compartment, or recycled to
the cell surface. In some embodiments, the variants of the invention bind to a cell-
surface antigen that internalizes. In other embodiments, antibodies of the invention
may be targeted to specific organelles or compartments of the cell. In yet other
embodiments, the variants of the invention may be recycled to the cell surface or
periphery after internalization.
In a specific embodiment, the antibody of the invention is specific for p-Selectin,
CD9, CD19, CD81, CCR5 or CXCR5, IL17a or Il-33.
Antibody Preparation
In the preferred embodiment of the invention, the Fc region-containing polypeptide
which is modified according to the teachings herein is an antibody. Techniques for
producing antibodies follow:
Antigen Selection and Preparation
Where the polypeptide is an antibody, it is directed against an antigen of interest.
Preferably, the antigen is a biologically important polypeptide and administration
of the antibody to a mammal suffering from a disease or disorder can result in a
therapeutic benefit in that mammal. However, antibodies directed against
nonpolypeptide antigens (such as tumor-associated glycolipid antigens; see U.S.
Pat. No. 5,091,178) are also contemplated.
Where the antigen is a polypeptide, it may be a transmembrane molecule (e.g.
receptor) or ligand such as a growth factor. Exemplary antigens include molecules
such as renin; a growth hormone, including human growth hormone and bovine
growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid
stimulating hormone; lipoproteins; alphaantitrypsin; insulin A-chain; insulin B-
chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone;
glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor (TF), and
von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic
factor; lung surfactant; a plasminogen activator, such as urokinase or human urine
or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic
growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES
(regulated on activation normally T-cell expressed and secreted); human
macrophage inflammatory protein (MIPalpha); a serum albumin such as human
serum albumin; Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain;
prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as
beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associated antigen (CTLA),
such as CTLA-4; inhibin; activin; vascular endothelial growth factor (VEGF);
receptors for hormones or growth factors; protein A or D; rheumatoid factors; a
neurotrophic factor such as bone-derived neurotrophic factor (BDNF),
neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor
such as NGF-β; platelet-derived growth factor (PDGF); fibroblast growth factor
such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth
factor (TGF) such as TGF-alpha and TGF-beta, including TGF-β1, TGF-β2, TGF-
β3, TGF-β4, or TGF-β5; insulin-like growth factor-I and -II (IGF-I and IGF-II);
des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD
proteins such as CD4, CD8, CD19 and CD20; erythropoietin; osteoinductive
factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as
interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-
CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxide
dismutase; surface membrane proteins; decay accelerating factor; viral antigen such
as, for example, a portion of the AIDS envelope; transport proteins; homing
receptors; addressins; regulatory proteins; integrins such as CD11a, CD11b,
CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as
HER2, HER3 or HER4 receptor; and fragments of any of the above-listed
polypeptides.
Preferred molecular targets for antibodies encompassed by the present invention
include CD proteins such as CD4, CD8, CD19, CD20 and CD34; members of the
ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor;
cell adhesion molecules such as LFA-1, Mac1, p150.95, VLA-4, ICAM-1, VCAM,
α4/β7 integrin, and αv/β3 integrin including either α or β subunits thereof (e.g. anti-
CD11a, anti-CD18 or anti-CD11b antibodies); growth factors such as VEGF; tissue
factor (TF); alpha interferon (α-IFN); an interleukin, such as IL-8; IgE; blood group
antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein
C etc.
Soluble antigens or fragments thereof, optionally conjugated to other molecules,
can be used as immunogens for generating antibodies. For transmembrane
molecules, such as receptors, fragments of these (e.g. the extracellular domain of a
receptor) can be used as the immunogen. Alternatively, cells expressing the
transmembrane molecule can be used as the immunogen. Such cells can be derived
from a natural source (e.g. cancer cell lines) or may be cells which have been
transformed by recombinant techniques to express the transmembrane molecule.
Other antigens and forms thereof useful for preparing antibodies will be apparent to
those in the art.
Polyclonal Antibodies
Polyclonal antibodies are preferably raised in animals by multiple subcutaneous
(sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may
be useful to conjugate the relevant antigen to a protein that is immunogenic in the
species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine
thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing
agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through
cysteine residues), N-hydroxysuccinimide (through lysine residues),
glutaraldehyde, succinic anhydride, SOCl , or carbodiimide where R and R are
different alkyl groups.
Animals are immunized against the antigen, immunogenic conjugates, or
derivatives by combining, e.g., 100 μg or 5 μg of the protein or conjugate (for
rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and
injecting the solution intradermally at multiple sites. One month later the animals
are boosted with for example 1/10 of the original amount of peptide or conjugate in
Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14
days later the animals are bled and the serum is assayed for antibody titer. Animals
are boosted until the titer plateaus. Preferably, the animal is boosted with the
conjugate of the same antigen, but conjugated to a different protein and/or through
a different cross-linking reagent. Conjugates also can be made in recombinant cell
culture as protein fusions. Also, aggregating agents such as alum are suitably used
to enhance the immune response.
Monoclonal Antibodies
Monoclonal antibodies may be made using the hybridoma method first described
by Kohler, et al., Nature, 256 (1975) 495, or may be made by recombinant DNA
methods (U.S. Pat. No. 4,816,567).
In the hybridoma method, a mouse or other appropriate host animal, such as a
hamster or macaque monkey, is immunized as hereinabove described to elicit
lymphocytes that produce or are capable of producing antibodies that will
specifically bind to the protein used for immunization. Alternatively, lymphocytes
may be immunized in vitro. Lymphocytes then are fused with myeloma cells using
a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell
(Goding, Monoclonal Antibodies: Principles and Practice, Academic Press (1986)
pp. 59-103).
The hybridoma cells thus prepared are seeded and grown in a suitable culture
medium that preferably contains one or more substances that inhibit the growth or
survival of the unfused, parental myeloma cells. For example, if the parental
myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase
(HGPRT or HPRT), the culture medium for the hybridomas typically will include
hypoxanthine, aminopterin, and thymidine (HAT medium), which substances
prevent the growth of HGPRT-deficient cells.
Preferred myeloma cells are those that fuse efficiently, support stable high-level
production of antibody by the selected antibody-producing cells, and are sensitive
to a medium such as HAT medium. Among these, preferred myeloma cell lines are
murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse
tumors available from the Salk Institute Cell Distribution Center, San Diego, Calif.
USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture
Collection, Rockville, Md. USA. Human myeloma and mouse-human
heteromyeloma cell lines also have been described for the production of human
monoclonal antibodies (Kozbor, J., Immunol. 133 (1984) 3001; Brodeur, et al.,
Monoclonal Antibody Production Techniques and Applications, Marcel Dekker,
Inc., New York (1987) pp. 51-63).
Culture medium in which hybridoma cells are growing is assayed for production of
monoclonal antibodies directed against the antigen. Preferably, the binding
specificity of monoclonal antibodies produced by hybridoma cells is determined by
immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay
(RIA) or enzyme-linked immunoabsorbent assay (ELISA).
After hybridoma cells are identified that produce antibodies of the desired
specificity, affinity, and/or activity, the clones may be subcloned by limiting
dilution procedures and grown by standard methods (Goding, Monoclonal
Antibodies: Principles and Practice, Academic Press (1986) pp. 59-103). Suitable
culture media for this purpose include, for example, D-MEM or RPMI-1640
medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors
in an animal.
The monoclonal antibodies secreted by the subclones are suitably separated from
the culture medium, ascites fluid, or serum by conventional immunoglobulin
purification procedures such as, for example, protein A-Sepharose, hydroxylapatite
chromatography, gel electrophoresis, dialysis, or affinity chromatography.
DNA encoding the monoclonal antibodies is readily isolated and sequenced using
conventional procedures (e.g., by using oligonucleotide probes that are capable of
binding specifically to genes encoding the heavy and light chains of the
monoclonal antibodies). The hybridoma cells serve as a preferred source of such
DNA. Once isolated, the DNA may be placed into expression vectors, which are
then transfected into host cells such as E. coli cells, simian COS cells, Chinese
hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce
immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the
recombinant host cells. Recombinant production of antibodies will be described in
more detail below.
In a further embodiment, antibodies or antibody fragments can be isolated from
antibody phage libraries generated using the techniques described in McCafferty,
J., et al., Nature 348 (1990) 552-554. Clackson, et al., Nature 352 (1991) 624-628
and Marks, et al., J. Mol. Biol. 222 (1991) 581-597 describe the isolation of murine
and human antibodies, respectively, using phage libraries. Subsequent publications
describe the production of high affinity (nM range) human antibodies by chain
shuffling (Marks, et al., Bio/Technology 10 (1992) 779-783), as well as
combinatorial infection and in vivo recombination as a strategy for constructing
very large phage libraries (Waterhouse, et al., Nuc. Acids. Res. 21 (1993) 2265-
2266). Thus, these techniques are viable alternatives to traditional monoclonal
antibody hybridoma techniques for isolation of monoclonal antibodies.
The DNA also may be modified, for example, by substituting the coding sequence
for human heavy- and light-chain constant domains in place of the homologous
murine sequences (U.S. Pat. No. 4,816,567; Morrison, et al., Proc. Natl. Acad. Sci.
USA, 81 (1984) 6851-6855), or by covalently joining to the immunoglobulin
coding sequence all or part of the coding sequence for a non-immunoglobulin
polypeptide.
Typically such non-immunoglobulin polypeptides are substituted for the constant
domains of an antibody, or they are substituted for the variable domains of one
antigen-combining site of an antibody to create a chimeric bivalent antibody
comprising one antigen-combining site having specificity for an antigen and
another antigen-combining site having specificity for a different antigen.
Antibody Affinity
In certain embodiments, an antibody provided herein has a dissociation constant
(Kd) of ≤ 1μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM
-8 -8 -13 -9 -13
(e.g. 10 M or less, e.g. from 10 M to 10 M, e.g., from 10 M to 10 M).
In one embodiment, Kd is measured by a radiolabeled antigen or Fc receptor
binding assay (RIA) performed with the Fab version of an antibody of interest and
its antigen as described by the following assay. Solution binding affinity of Fabs
for antigen is measured by equilibrating Fab with a minimal concentration of ( I)-
labeled antigen in the presence of a titration series of unlabeled antigen, then
capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen, et
al., J. Mol. Biol. 293 (1999) 865-881). To establish conditions for the assay,
MICROTITER multi-well plates (Thermo Scientific) are coated overnight with 5
μg/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate
(pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS
for two to five hours at room temperature (approximately 23°C). In a non-
adsorbent plate (Nunc #269620), 100 pM or 26 pM [ I]-antigen are mixed with
serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-
VEGF antibody, Fab-12, in Presta, et al., Cancer Res. 57 (1997) 4593-4599). The
Fab of interest is then incubated overnight; however, the incubation may continue
for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached.
Thereafter, the mixtures are transferred to the capture plate for incubation at room
temperature (e.g., for one hour). The solution is then removed and the plate washed
eight times with 0.1% polysorbate 20 (TWEEN-20 ) in PBS. When the plates have
dried, 150 μl/well of scintillant (MICROSCINT-20 ; Packard) is added, and the
plates are counted on a TOPCOUNT gamma counter (Packard) for ten minutes.
Concentrations of each Fab that give less than or equal to 20% of maximal binding
are chosen for use in competitive binding assays.
According to another embodiment, Kd is measured using surface plasmon
resonance assays using a BIACORE -2000 or a BIACORE -3000 (BIAcore, Inc.,
Piscataway, NJ) at 25°C with immobilized antigen or Fc receptor CM5 chips at ~10
response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5,
BIACORE, Inc.) are activated with N-ethyl-N’- (3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to
the supplier’s instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8,
to 5 μg/ml (~0.2 μM) before injection at a flow rate of 5 μl/minute to achieve
approximately 10 response units (RU) of coupled protein. Following the injection
of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics
measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in
PBS with 0.05% polysorbate 20 (TWEEN-20 ) surfactant (PBST) at 25°C at a
flow rate of approximately 25 μl/min. Association rates (k ) and dissociation rates
(k ) are calculated using a simple one-to-one Langmuir binding model
(BIACORE Evaluation Software version 3.2) by simultaneously fitting the
association and dissociation sensograms. The equilibrium dissociation constant
(Kd) is calculated as the ratio k /k See, e.g., Chen, et al., J. Mol. Biol. 293
off on.
6 -1 -1
(1999) 865-881. If the on-rate exceeds 10 M s by the surface plasmon
resonance assay above, then the on-rate can be determined by using a fluorescent
quenching technique that measures the increase or decrease in fluorescence
emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at
C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence
of increasing concentrations of antigen as measured in a spectrometer, such as a
stop-flow equipped spectrophometer (Aviv Instruments) or a 8000-series SLM-
AMINCO spectrophotometer (ThermoSpectronic) with a stirred cuvette.
In certain embodiments, an antibody provided herein is an antibody fragment.
Antibody fragments include, but are not limited to, Fab, Fab’, Fab’-SH, F(ab’) , Fv,
and scFv fragments, and other fragments described below. For a review of certain
antibody fragments, see Hudson, et al., Nat. Med. 9 (2003) 129-134. For a review
of scFv fragments, see, e.g., Pluckthün, in The Pharmacology of Monoclonal
Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York),
pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. US 5,571,894
and US 5,587,458. For discussion of Fab and F(ab') fragments comprising salvage
receptor binding epitope residues and having increased in vivo half-life, see U.S.
Patent No. US 5,869,046.
Diabodies are antibody fragments with two antigen-binding sites that may be
bivalent or bispecific. See, for example, EP 0 404 097; ; Hudson,
et al., Nat. Med. 9 (2003) 129-134; and Hollinger, et al., Proc. Natl. Acad. Sci.
USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in
Hudson, et al., Nat. Med. 9 (2003) 129-134.
Single-domain antibodies are antibody fragments comprising all or a portion of the
heavy chain variable domain or all or a portion of the light chain variable domain
of an antibody. In certain embodiments, a single-domain antibody is a human
single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No.
US 6,248,516 B1).
Antibody fragments can be made by various techniques, including but not limited
to proteolytic digestion of an intact antibody as well as production by recombinant
host cells (e.g. E. coli or phage), as described herein.
Chimeric and Humanized Antibodies
In certain embodiments, an antibody provided herein is a chimeric antibody.
Certain chimeric antibodies are described, e.g., in U.S. Patent No. US 4,816,567;
and Morrison, et al., Proc. Natl. Acad. Sci. USA, 81 (1984) 6851-6855). In one
example, a chimeric antibody comprises a non-human variable region (e.g., a
variable region derived from a mouse, rat, hamster, rabbit, or non-human primate,
such as a monkey) and a human constant region. In a further example, a chimeric
antibody is a “class switched” antibody in which the class or subclass has been
changed from that of the parent antibody. Chimeric antibodies include antigen-
binding fragments thereof.
In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a
non-human antibody is humanized to reduce immunogenicity to humans, while
retaining the specificity and affinity of the parental non-human antibody.
Generally, a humanized antibody comprises one or more variable domains in which
HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody,
and FRs (or portions thereof) are derived from human antibody sequences. A
humanized antibody optionally will also comprise at least a portion of a human
constant region. In some embodiments, some FR residues in a humanized antibody
are substituted with corresponding residues from a non-human antibody (e.g., the
antibody from which the HVR residues are derived), e.g., to restore or improve
antibody specificity or affinity.
Humanized antibodies and methods of making them are reviewed, e.g., in
Almagro, and Fransson, Front. Biosci. 13 (2008) 1619-1633, and are further
described, e.g., in Riechmann, et al., Nature 332 (1988) 323-329; Queen, et al.,
Proc. Nat’l Acad. Sci. USA 86 (1989) 10029-10033; US Patent Nos. 5,821,337,
7,527,791, 6,982,321, and 7,087,409; Kashmiri, et al., Methods 36 (2005) 25-34
(describing SDR (a-CDR) grafting); Padlan, Mol. Immunol. 28 (1991) 489-498
(describing “resurfacing”); Dall’Acqua, et al., Methods 36 (2005) 43-60
(describing “FR shuffling”); and Osbourn, et al., Methods 36 (2005)61-68 and
Klimka, et al., Br. J. Cancer, 83 (2000) 252-260 (describing the “guided selection”
approach to FR shuffling).
Human framework regions that may be used for humanization include but are not
limited to: framework regions selected using the "best-fit" method (see, e.g., Sims,
et al., J. Immunol. 151 (1993) 2296); framework regions derived from the
consensus sequence of human antibodies of a particular subgroup of light or heavy
chain variable regions (see, e.g., Carter, et al., Proc. Natl. Acad. Sci. USA, 89
(1992) 4285; and Presta, et al., J. Immunol., 151 (1993) 2623); human mature
(somatically mutated) framework regions or human germline framework regions
(see, e.g., Almagro, and Fransson, Front. Biosci. 13 (2008) 1619-1633); and
framework regions derived from screening FR libraries (see, e.g., Baca, et al., J.
Biol. Chem. 272 (1997) 10678-10684 and Rosok, et al., J. Biol. Chem. 271 (1996)
22611-22618).
Human Antibodies
In certain embodiments, an antibody provided herein is a human antibody. Human
antibodies can be produced using various techniques known in the art. Human
antibodies are described generally in van Dijk, and van de Winkel, Curr. Opin.
Pharmacol. 5 (2001) 368-74 and Lonberg, Curr. Opin. Immunol. 20 (2008) 450-
459.
Human antibodies may be prepared by administering an immunogen to a transgenic
animal that has been modified to produce intact human antibodies or intact
antibodies with human variable regions in response to antigenic challenge. Such
animals typically contain all or a portion of the human immunoglobulin loci, which
replace the endogenous immunoglobulin loci, or which are present
extrachromosomally or integrated randomly into the animal’s chromosomes. In
such transgenic mice, the endogenous immunoglobulin loci have generally been
inactivated. For review of methods for obtaining human antibodies from transgenic
animals, see Lonberg, Nat. Biotech. 23 (2005) 1117-1125. See also, e.g., U.S.
Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE technology;
U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No.
7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application
Publication No. US 2007/0061900, describing VELOCIMOUSE® technology).
Human variable regions from intact antibodies generated by such animals may be
further modified, e.g., by combining with a different human constant region.
Human antibodies can also be made by hybridoma-based methods. Human
myeloma and mouse-human heteromyeloma cell lines for the production of human
monoclonal antibodies have been described. (See, e.g., Kozbor, J. Immunol., 133
(1984) 3001; Brodeur, et al., Monoclonal Antibody Production Techniques and
Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63; and Boerner, et
al., J. Immunol., 147 (1991) 86.) Human antibodies generated via human B-cell
hybridoma technology are also described in Li, et al., Proc. Natl. Acad. Sci. USA,
103 (2006) 3557-3562. Additional methods include those described, for example,
in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM
antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4) (2006)
265-268 (describing human-human hybridomas). Human hybridoma technology
(Trioma technology) is also described in Vollmers, and Brandlein, Histology and
Histopathology 20(3) (2005) 927-937 and Vollmers, and Brandlein, Methods and
Findings in Experimental and Clinical Pharmacology 27(3) (2005) 185-91.
Human antibodies may also be generated by isolating Fv clone variable domain
sequences selected from human-derived phage display libraries. Such variable
domain sequences may then be combined with a desired human constant domain.
Techniques for selecting human antibodies from antibody libraries are described
below.
Library-Derived Antibodies
Antibodies of the invention may be isolated by screening combinatorial libraries
for antibodies with the desired activity or activities. For example, a variety of
methods are known in the art for generating phage display libraries and screening
such libraries for antibodies possessing the desired binding characteristics. Such
methods are reviewed, e.g., in Hoogenboom, H.R., et al., in Methods in Molecular
Biology 178 (2002) 1-37 (O’Brien et al., ed., Human Press, Totowa, NJ, 2001) and
further described, e.g., in the McCafferty, J., et al., Nature 348 (1990) 552-554;
Clackson, et al., Nature 352 (1991) 624-628; Marks, et al., J. Mol. Biol. 222 (1992)
581-597; Marks, and Bradbury, in Methods in Molecular Biology 248 161-175
(Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu, et al., J. Mol. Biol. 338(2)
(2004) 299-310; Lee, et al., J. Mol. Biol. 340(5) (2004) 1073-1093; Fellouse, Proc.
Natl. Acad. Sci. USA 101(34) (2004) 12467-12472; and Lee, et al., J. Immunol.
Methods 284(1-2) (2004) 119-132.
In certain phage display methods, repertoires of VH and VL genes are separately
cloned by polymerase chain reaction (PCR) and recombined randomly in phage
libraries, which can then be screened for antigen-binding phage as described in
Winter, et al., Ann. Rev. Immunol., 12 (1994) 433-455. Phage typically display
antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
Libraries from immunized sources provide high-affinity antibodies to the
immunogen without the requirement of constructing hybridomas. Alternatively, the
naive repertoire can be cloned (e.g., from human) to provide a single source of
antibodies to a wide range of non-self and also self antigens without any
immunization as described by Griffiths, et al., EMBO J, 12 (1993) 725-734.
Finally, naive libraries can also be made synthetically by cloning unrearranged V-
gene segments from stem cells, and using PCR primers containing random
sequence to encode the highly variable CDR3 regions and to accomplish
rearrangement in vitro, as described by Hoogenboom, and Winter, J. Mol. Biol.,
227 (1992) 381-388. Patent publications describing human antibody phage libraries
include, for example: US Patent No. 5,750,373, and US Patent Publication Nos.
2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,
2007/0237764, 2007/0292936, and 2009/0002360.
Antibodies or antibody fragments isolated from human antibody libraries are
considered human antibodies or human antibody fragments herein.
Multispecific Antibodies
In certain embodiments, an antibody provided herein is a multispecific antibody,
e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that
have binding specificities for at least two different sites. In certain embodiments,
one of the binding specificities is for a specific antigen and the other is for any
other antigen. In certain embodiments, bispecific antibodies may bind to two
different epitopes of the antigen. Bispecific antibodies may also be used to localize
cytotoxic agents to cells which express the antigen to which the antibody binds.
Bispecific antibodies can be prepared as full length antibodies or antibody
fragments.
Techniques for making multispecific antibodies include, but are not limited to,
recombinant co-expression of two immunoglobulin heavy chain-light chain pairs
having different specificities (see Milstein, and Cuello, Nature 305 (1983) 537,
WO 93/08829, and Traunecker, et al., EMBO J. 10 (1991) 3655), and “knob-in-
hole” engineering (see, e.g., U.S. Patent No. 5,731,168). Multi-specific antibodies
may also be made by engineering electrostatic steering effects for making antibody
Fc-heterodimeric molecules ( A1); cross-linking two or more
antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan, et al.,
Science, 229 (1985) 81); using leucine zippers to produce bi-specific antibodies
(see, e.g., Kostelny, et al., J. Immunol., 148(5) (1992) 1547-1553); using "diabody"
technology for making bispecific antibody fragments (see, e.g., Hollinger, et al.,
Proc. Natl. Acad. Sci. USA, 90 (1993) 6444-6448); and using single-chain Fv (sFv)
dimers (see, e.g. Gruber, et al., J. Immunol., 152 (1994) 5368); and preparing
trispecific antibodies as described, e.g., in Tutt, et al., J. Immunol. 147 (1991) 60.
Engineered antibodies with three or more functional antigen binding sites,
including “Octopus antibodies,” are also included herein (see, e.g.
US 2006/0025576 A1).
The antibody or fragment herein also includes a “Dual Acting FAb” or “DAF”
comprising an antigen binding site that binds to a specific antigen as well as
another, different antigen (see, US 2008/0069820, for example).
Antibody Variants with altered binding affinity to the antigen
In certain embodiments, it may be desirable to improve the binding affinity to the
antigen and/or other biological properties of the antibody. Amino acid sequence
variants of an antibody may be prepared by introducing appropriate modifications
into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such
modifications include, for example, deletions from, and/or insertions into and/or
substitutions of residues within the amino acid sequences of the antibody. Any
combination of deletion, insertion, and substitution can be made to arrive at the
final construct, provided that the final construct possesses the desired
characteristics, e.g., antigen-binding.
Substitution, Insertion, and Deletion Variants
In certain embodiments, polypeptides comprising Fc variants additionally have one
or more amino acid substitutions at other parts than the Fc part, are provided. Sites
of interest for substitutional mutagenesis include the HVRs and FRs. Conservative
substitutions are shown in Table 1 under the heading of "conservative
substitutions."More substantial changes are provided in Table 1 under the heading
of "exemplary substitutions," and as further described below in reference to amino
acid side chain classes. Amino acid substitutions may be introduced into an
antibody of interest and the products screened for a desired activity, e.g.,
retained/improved antigen binding, or decreased immunogenicity.
Table 1:
Original Exemplary Substitutions Conservative
Residue Substitutions
Ala (A) Val; Leu; Ile Val
Arg (R) Lys; Gln; Asn Lys
Asn (N) Gln; His; Asp, Lys; Arg Gln
Asp (D) Glu; Asn Glu
Cys (C) Ser; Ala Ser
Gln (Q) Asn; Glu Asn
Glu (E) Asp; Gln Asp
Gly (G) Ala Ala
His (H) Asn; Gln; Lys; Arg Arg
Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu
Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile
Lys (K) Arg; Gln; Asn Arg
Met (M) Leu; Phe; Ile Leu
Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
grouped according to common side-chain properties:
(1) hydrophobic: Ile, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
Non-conservative substitutions will entail exchanging a member of one of these
classes for another class.
One type of substitutional variant involves substituting one or more hypervariable
region residues of a parent antibody (e.g. a humanized or human antibody).
Generally, the resulting variant(s) selected for further study will have modifications
(e.g., improvements) in certain biological properties (e.g., increased affinity,
reduced immunogenicity) relative to the parent antibody and/or will have
substantially retained certain biological properties of the parent antibody. An
exemplary substitutional variant is an affinity matured antibody, which may be
conveniently generated, e.g., using phage display-based affinity maturation
techniques such as those described herein. Briefly, one or more HVR residues are
mutated and the variant antibodies displayed on phage and screened for a particular
biological activity (e.g. binding affinity).
Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody
affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded
by codons that undergo mutation at high frequency during the somatic maturation
process (see, e.g., Chowdhury, Methods Mol. Biol. 207 (2008) 179-196), and/or
SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding
affinity. Affinity maturation by constructing and reselecting from secondary
libraries has been described, e.g., in Hoogenboom, et al., in Methods in Molecular
Biology 178 (2002) 1-37 (O’Brien et al., ed., Human Press, Totowa, NJ, (2001)). In
some embodiments of affinity maturation, diversity is introduced into the variable
genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR,
chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is
then created. The library is then screened to identify any antibody variants with the
desired affinity. Another method to introduce diversity involves HVR-directed
approaches, in which several HVR residues (e.g., 4-6 residues at a time) are
randomized. HVR residues involved in antigen binding may be specifically
identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and
CDR-L3 in particular are often targeted.
In certain embodiments, substitutions, insertions, or deletions may occur within
one or more HVRs so long as such alterations do not substantially reduce the
ability of the antibody to bind antigen. For example, conservative alterations (e.g.,
conservative substitutions as provided herein) that do not substantially reduce
binding affinity may be made in HVRs. Such alterations may be outside of HVR
“hotspots” or SDRs. In certain embodiments of the variant VH and VL sequences
provided above, each HVR either is unaltered, or contains no more than one, two or
three amino acid substitutions.
A useful method for identification of residues or regions of an antibody that may be
targeted for mutagenesis is called "alanine scanning mutagenesis" as described by
Cunningham, and Wells, Science 244 (1989) 1081-1085. In this method, a residue
or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu)
are identified and replaced by a neutral or negatively charged amino acid (e.g.,
alanine or polyalanine) to determine whether the interaction of the antibody with
antigen is affected. Further substitutions may be introduced at the amino acid
locations demonstrating functional sensitivity to the initial substitutions.
Alternatively, or additionally, a crystal structure of an antigen-antibody complex to
identify contact points between the antibody and antigen. Such contact residues and
neighboring residues may be targeted or eliminated as candidates for substitution.
Variants may be screened to determine whether they contain the desired properties.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions
ranging in length from one residue to polypeptides containing a hundred or more
residues, as well as intrasequence insertions of single or multiple amino acid
residues. Examples of terminal insertions include an antibody with an N-terminal
methionyl residue. Other insertional variants of the antibody molecule include the
fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a
polypeptide which increases the serum half-life of the antibody.
Glycosylation variants
In certain embodiments, an antibody provided herein is altered to increase or
decrease the extent to which the antibody is glycosylated. Addition or deletion of
glycosylation sites to an antibody may be conveniently accomplished by altering
the amino acid sequence such that one or more glycosylation sites is created or
removed.
Where the antibody comprises an Fc region, the carbohydrate attached thereto may
be altered. Native antibodies produced by mammalian cells typically comprise a
branched, biantennary oligosaccharide that is generally attached by an N-linkage to
Asn297 of the CH2 domain of the Fc region. See, e.g., Wright, et al., TIBTECH 15
(1997) 26-32. The oligosaccharide may include various carbohydrates, e.g.,
mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a
fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide
structure. In some embodiments, modifications of the oligosaccharide in an
antibody of the invention may be made in order to create antibody variants with
certain improved properties.
Polypeptides comprising Fc variants are further provided with sialylated
oligosaccharides, e.g., in which a differential sialylation of the Fc core
oligosaccharide attached to the Fc region of the antibody is provided. Such
polypeptides may have increased sialylation and/or decreased ADCC function.
Examples of such antibody variants are described e.g. by Kaneko, et al., Science
313 (2006) 670–673.
Cysteine engineered antibody variants
In certain embodiments, it may be desirable to create cysteine engineered
antibodies, e.g., “thioMAbs,” in which one or more residues of an antibody are
substituted with cysteine residues. In particular embodiments, the substituted
residues occur at accessible sites of the antibody. By substituting those residues
with cysteine, reactive thiol groups are thereby positioned at accessible sites of the
antibody and may be used to conjugate the antibody to other moieties, such as drug
moieties or linker-drug moieties, to create an immunoconjugate, as described
further herein. In certain embodiments, any one or more of the following residues
may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118
(EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain
Fc region. Cysteine engineered antibodies may be generated as described, e.g., in
U.S. Patent No. 7,521,541.
Antibody Derivatives
In certain embodiments, an antibody provided herein may be further modified to
contain additional nonproteinaceous moieties that are known in the art and readily
available. The moieties suitable for derivatization of the antibody include but are
not limited to water soluble polymers. Non-limiting examples of water soluble
polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of
ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl
alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane,
ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or
random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol,
propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-
polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and
mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in
manufacturing due to its stability in water. The polymer may be of any molecular
weight, and may be branched or unbranched. The number of polymers attached to
the antibody may vary, and if more than one polymer are attached, they can be the
same or different molecules. In general, the number and/or type of polymers used
for derivatization can be determined based on considerations including, but not
limited to, the particular properties or functions of the antibody to be improved,
whether the antibody derivative will be used in a therapy under defined conditions,
etc.
In another embodiment, conjugates of an antibody and nonproteinaceous moiety
that may be selectively heated by exposure to radiation are provided. In one
embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam, et al., Proc.
Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any
wavelength, and includes, but is not limited to, wavelengths that do not harm
ordinary cells, but which heat the nonproteinaceous moiety to a temperature at
which cells proximal to the antibody-nonproteinaceous moiety are killed.
Recombinant Methods and Compositions
Antibodies may be produced using recombinant methods and compositions, e.g., as
described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic acid
encoding an antibody variant described herein is provided. Such nucleic acid may
encode an amino acid sequence comprising the VL and/or an amino acid sequence
comprising the VH of the antibody (e.g., the light and/or heavy chains of the
antibody). In a further embodiment, one or more vectors (e.g., expression vectors)
comprising such nucleic acid are provided. In a further embodiment, a host cell
comprising such nucleic acid is provided. In one such embodiment, a host cell
comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid
that encodes an amino acid sequence comprising the VL of the antibody and an
amino acid sequence comprising the VH of the antibody, or (2) a first vector
comprising a nucleic acid that encodes an amino acid sequence comprising the VL
of the antibody and a second vector comprising a nucleic acid that encodes an
amino acid sequence comprising the VH of the antibody. In one embodiment, the
host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell
(e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an antibody
variant is provided, wherein the method comprises culturing a host cell comprising
a nucleic acid encoding the antibody, as provided above, under conditions suitable
for expression of the antibody, and optionally recovering the antibody from the
host cell (or host cell culture medium).
For recombinant production of an antibody variant, nucleic acid encoding an
antibody, e.g., as described above, is isolated and inserted into one or more vectors
for further cloning and/or expression in a host cell. Such nucleic acid may be
readily isolated and sequenced using conventional procedures (e.g., by using
oligonucleotide probes that are capable of binding specifically to genes encoding
the heavy and light chains of the antibody).
Suitable host cells for cloning or expression of antibody-encoding vectors include
prokaryotic or eukaryotic cells described herein. For example, antibodies may be
produced in bacteria, in particular when glycosylation and Fc effector function are
not needed. For expression of antibody fragments and polypeptides in bacteria, see,
e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton,
Methods in Molecular Biology 248 (2003) 245-254 (B.K.C. Lo, ed., Humana
Press, Totowa, NJ), describing expression of antibody fragments in E. coli.) After
expression, the antibody may be isolated from the bacterial cell paste in a soluble
fraction and can be further purified.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast
are suitable cloning or expression hosts for antibody-encoding vectors, including
fungi and yeast strains whose glycosylation pathways have been “humanized,”
resulting in the production of an antibody with a partially or fully human
glycosylation pattern. See Gerngross, Nat. Biotech. 22 (2004) 1409-1414, and Li,
et al., Nat. Biotech. 24 (2006) 210-215.
Suitable host cells for the expression of glycosylated antibody are also derived
from multicellular organisms (invertebrates and vertebrates). Examples of
invertebrate cells include plant and insect cells. Numerous baculoviral strains have
been identified which may be used in conjunction with insect cells, particularly for
transfection of Spodoptera frugiperda cells.
Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177,
6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES
technology for producing antibodies in transgenic plants).
Vertebrate cells may also be used as hosts. For example, mammalian cell lines that
are adapted to grow in suspension may be useful. Other examples of useful
mammalian host cell lines are monkey kidney CV1 line transformed by SV40
(COS-7); human embryonic kidney line (293 or kidney cells (BHK); mouse sertoli
cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23 (1980) 243-251);
monkey kidney cells (CV1); African green monkey kidney cells (VERO-76);
human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat
liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2);
mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, et
al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells. Other
useful mammalian host cell lines include Chinese hamster ovary (CHO) cells,
including DHFR CHO cells (Urlaub, et al., Proc. Natl. Acad. Sci. USA 77 (1980)
4216); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain
mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, and
Wu, Methods in Molecular Biology 248 (2003) 255-268 (B.K.C. Lo, ed., Humana
Press, Totowa, NJ).
Assays
Antibodies provided herein may be identified, screened for, or characterized for
their physical/chemical properties and/or biological activities by various assays
known in the art.
Binding assays and other assays
In one aspect, an antibody of the invention is tested for its antigen binding activity,
e.g., by known methods such as ELISA, Western blot, etc.
In an exemplary competition assay, immobilized antigen is incubated in a solution
comprising a first labeled antibody that binds to the antigen (e.g.,) and a second
unlabeled antibody that is being tested for its ability to compete with the first
antibody for binding to the antigen. The second antibody may be present in a
hybridoma supernatant. As a control, immobilized antigen is incubated in a
solution comprising the first labeled antibody but not the second unlabeled
antibody. After incubation under conditions permissive for binding of the first
antibody to the antigen, excess unbound antibody is removed, and the amount of
label associated with immobilized antigen is measured. If the amount of label
associated with immobilized antigen is substantially reduced in the test sample
relative to the control sample, then that indicates that the second antibody is
competing with the first antibody for binding to the antigen (See Harlow, and Lane
(1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory,
Cold Spring Harbor, NY).
Immunoconjugates
The invention also provides immunoconjugates comprising an antibody herein
conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or
drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active
toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or
radioactive isotopes.
In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in
which an antibody is conjugated to one or more drugs, including but not limited to
a maytansinoid (see U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent
EP 0 425 235 B1); an auristatin such as monomethylauristatin drug moieties DE
and DF (MMAE and MMAF) (see U.S. Patent Nos. 5,635,483 and 5,780,588, and
7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Patent Nos.
,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and
,877,296; Hinman, et al., Cancer Res. 53 (1993) 3336-3342; and Lode, et al.,
Cancer Res. 58 (1998) 2925-2928); an anthracycline such as daunomycin or
doxorubicin (see Kratz, et al., Current Med. Chem. 13 (2006) 477-523; Jeffrey, et
al., Bioorganic & Med. Chem. Letters 16 (2006) 358-362; Torgov, et al., Bioconj.
Chem. 16 (2005) 717-721; Nagy, et al., Proc. Natl. Acad. Sci. USA 97 (2000) 829-
834; Dubowchik, et al., Bioorg. & Med. Chem. Letters 12 (2002) 1529-1532; King,
et al., J. Med. Chem. 45 (2002) 4336-4343; and U.S. Patent No. 6,630,579);
methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel,
and ortataxel; a trichothecene; and CC1065.
In another embodiment, an immunoconjugate comprises an antibody as described
herein conjugated to an enzymatically active toxin or fragment thereof, including
but not limited to diphtheria A chain, nonbinding active fragments of diphtheria
toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A
chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins,
Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia
inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin,
restrictocin, phenomycin, enomycin, and the tricothecenes.
In another embodiment, an immunoconjugate comprises an antibody as described
herein conjugated to a radioactive atom to form a radioconjugate. A variety of
radioactive isotopes are available for the production of radioconjugates. Examples
211 131 125 90 186 188 153 212 32 212
include At , I , I , Y , Re , Re , Sm , Bi , P , Pb and radioactive
isotopes of Lu. When the radioconjugate is used for detection, it may comprise a
radioactive atom for scintigraphic studies, for example tc99m or I123, or a spin
label for nuclear magnetic resonance (NMR) imaging (also known as magnetic
resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111,
fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
Conjugates of an antibody and cytotoxic agent may be made using a variety of
bifunctional protein coupling agents such as N-succinimidyl(2-pyridyldithio)
propionate (SPDP), succinimidyl(N-maleimidomethyl) cyclohexane
carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters
(such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl
suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-
azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-
diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-
diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-
dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in
Vitetta, et al., Science 238 (1987) 1098. Carbonlabeled 1-
isothiocyanatobenzylmethyldiethylene triaminepentaacetic acid (MX-DTPA) is
an exemplary chelating agent for conjugation of radionucleotide to the antibody.
See WO 94/11026. The linker may be a “cleavable linker” facilitating release of a
cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive
linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari, et
al., Cancer Res. 52 (1992) 127-131; U.S. Patent No. 5,208,020) may be used.
The immunuoconjugates or ADCs herein expressly contemplate, but are not limited
to such conjugates prepared with cross-linker reagents including, but not limited to,
BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB,
SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS,
sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-
vinylsulfone)benzoate) which are commercially available (e.g., from Pierce
Biotechnology, Inc., Rockford, IL., U.S.A).
Methods and Compositions for Diagnostics and Detection
In certain embodiments, any of the antibody variants provided herein is useful for
detecting the presence of the antigen binding to that antibody in a biological
sample. The term “detecting” as used herein encompasses quantitative or
qualitative detection. In certain embodiments, a biological sample comprises a cell
or tissue.
In one embodiment, an antibody variant for use in a method of diagnosis or
detection is provided. In a further aspect, a method of detecting the presence of the
antigen to which said antibody variant binds in a biological sample is provided. In
certain embodiments, the method comprises contacting the biological sample with
an antibody as described herein under conditions permissive for binding of the
antibody to the antigen, and detecting whether a complex is formed between the
antibody and the antigen. Such method may be an in vitro or in vivo method. In one
embodiment, an antibody variant is used to select subjects eligible for therapy with
an antibody, e.g. where the antigen to which said antibody binds is a biomarker for
selection of patients.
Exemplary disorders that may be diagnosed using an antibody of the invention
include cancer, cardiovascular diseases, neuronal disorders and diabetes.
In certain embodiments, labeled antibody variants are provided. Labels include, but
are not limited to, labels or moieties that are detected directly (such as fluorescent,
chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well
as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through
an enzymatic reaction or molecular interaction. Exemplary labels include, but are
32 14 125 3 131
not limited to, the radioisotopes P, C, I, H, and I, fluorophores such as rare
earth chelates or fluorescein and its derivatives, rhodamine and its derivatives,
dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase
(U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish
peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme,
saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose
phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine
oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye
precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin
labels, bacteriophage labels, stable free radicals, and the like.
Pharmaceutical Formulations
Pharmaceutical formulations of an antibody variant as described herein are
prepared by mixing such antibody having the desired degree of purity with one or
more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical
Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations
or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic
to recipients at the dosages and concentrations employed, and include, but are not
limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants
including ascorbic acid and methionine; preservatives (such as
octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol;
alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids
such as glycine, glutamine, asparagine, histidine, arginine, or lysine;
monosaccharides, disaccharides, and other carbohydrates including glucose,
mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal
complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as
polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein
further include insterstitial drug dispersion agents such as soluble neutral-active
hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20
hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX , Baxter International,
Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are
described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one
aspect, a sHASEGP is combined with one or more additional
glycosaminoglycanases such as chondroitinases.
Exemplary lyophilized antibody formulations are described in US Patent No.
6,267,958. Aqueous antibody formulations include those described in US Patent
No. 6,171,586 and , the latter formulations including a histidine-
acetate buffer.
The formulation herein may also contain more than one active ingredients as
necessary for the particular indication being treated, preferably those with
complementary activities that do not adversely affect each other. Such active
ingredients are suitably present in combination in amounts that are effective for the
purpose intended.
Active ingredients may be entrapped in microcapsules prepared, for example, by
coacervation techniques or by interfacial polymerization, for example,
hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate)
microcapsules, respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's
Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
Sustained-release preparations may be prepared. Suitable examples of sustained-
release preparations include semipermeable matrices of solid hydrophobic
polymers containing the antibody, which matrices are in the form of shaped
articles, e.g. films, or microcapsules.
The formulations to be used for in vivo administration are generally sterile. Sterility
may be readily accomplished, e.g., by filtration through sterile filtration
membranes.
Therapeutic Methods and Compositions
Any of the polypeptides provided herein may be used in therapeutic methods.
In a specific aspect of the invention the polypeptide according to the invention are
used for treating a disease. In a more specific aspect, the disease is such, that it is
favorable that the effector function of the variant is strongly, at least by 50%,
reduced compared to the polypeptide comprising the wildtype Fc polypeptide.
In a specific aspect the polypeptide according to the invention is used in the
manufacture of a medicament for the treatment of a disease, wherein it is favorable
that the effector function of the polypeptide is strongly reduced compared to a
wildtype Fc polypeptide. In a further specific aspect the polypeptide according to
the invention is used in the manufacture of a medicament for the treatment of a
disease, wherein it is favorable that the effector function of the polypeptide is
reduced compared to a wildtype Fc polypeptide, by at least 20%.
A further aspect is a method of treating an individual having a disease, wherein it is
favorable that the effector function of the variant is strongly reduced compared to a
wildtype Fc polypeptide, comprising administering to the individual an effective
amount of the polypeptide according to the invention.
A strong reduction of effector function is a reduction of effector function by at least
50 % of the effector function induced by the wildtype polypeptide.
Such diseases are for example all diseases where the targeted cell should not be
destroyed by for example ADCC, ADCP or CDC. Moreover, this is true for those
antibodies that are designed to deliver a drug (e.g., toxins and isotopes) to the target
cell where the Fc/FcγR mediated effector functions bring healthy immune cells into
the proximity of the deadly payload, resulting in depletion of normal lymphoid
tissue along with the target cells (Hutchins, et al, PNAS USA 92 (1995) 11980-
11984; White, et al, Annu Rev Med 52 (2001) 125-145). In these cases the use of
antibodies that poorly recruit complement or effector cells would be of tremendous
benefit (see for example, Wu, et al., Cell Immunol 200 (2000) 16-26; Shields, et
al., J. Biol Chem 276(9) (2001) 6591-6604; US 6,194,551; US 5,885,573 and PCT
publication WO 04/029207).
In other instances, for example, where blocking the interaction of a widely
expressed receptor with its cognate ligand is the objective, it would be
advantageous to decrease or eliminate all antibody effector function to reduce
unwanted toxicity. Also, in the instance where a therapeutic antibody exhibited
promiscuous binding across a number of human tissues it would be prudent to limit
the targeting of effector function to a diverse set of tissues to limit toxicity.
Also for agonist antibodies it would be very helpful if these antibodies exhibit
reduced effector function.
The conditions which can be treated with the polypeptide variant are many and
include cancer (e.g. where the antibody variant binds the HER2 receptor,
angiopoietin receptor or vascular endothelial growth factor (VEGF)); allergic
conditions such as asthma (with an anti-IgE antibody); and LFAmediated
disorders (e.g. where the polypeptide variant is an anti-LFA-1 or anti-ICAM-1
antibody), neurological and metabolic disorders.
Where the antibody binds the HER2 receptor, the disorder preferably is HER2-
expressing cancer, e.g. a benign or malignant tumor characterized by
overexpression of the HER2 receptor. Such cancers include, but are not limited to,
breast cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung
cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer,
ovarian cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer,
endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer,
prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types
of head and neck cancer.
The polypeptide or antibody variant is administered by any suitable means,
including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal,
and, if desired for local immunosuppressive treatment, intralesional administration.
Parenteral infusions include intramuscular, intravenous, intraarterial,
intraperitoneal, or subcutaneous administration. In addition, the antibody variant is
suitably administered by pulse infusion, particularly with declining doses of the
polypeptide variant. Preferably the dosing is given by injections, most preferably
intravenous or subcutaneous injections, depending in part on whether the
administration is brief or chronic.
For the prevention or treatment of disease, the appropriate dosage of polypeptide or
antibody variant will depend on the type of disease to be treated, the severity and
course of the disease, whether the polypeptide variant is administered for
preventive or therapeutic purposes, previous therapy, the patient's clinical history
and response to the polypeptide variant, and the discretion of the attending
physician. The polypeptide variant is suitably administered to the patient at one
time or over a series of treatments.
Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g.,
0.1-20 mg/kg) of polypeptide or antibody variant is an initial candidate dosage for
administration to the patient, whether, for example, by one or more separate
administrations, or by continuous infusion. A typical daily dosage might range
from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned
above. For repeated administrations over several days or longer, depending on the
condition, the treatment is sustained until a desired suppression of disease
symptoms occurs. However, other dosage regimens may be useful. The progress of
this therapy is easily monitored by conventional techniques and assays.
In certain embodiments, the invention provides an antibody variant or polypeptide
for use in a method of treating an individual having cancer comprising
administering to the individual an effective amount of the antibody variant. In one
such embodiment, the method further comprises administering to the individual an
effective amount of at least one additional therapeutic agent, e.g., as described
below. In further embodiments, the invention provides an antibody variant for use
in inhibiting angiogenesis, inhibiting cell proliferation or depleting B-cells in an
individual comprising administering to the individual an effective of the antibody
variant to inhibit angiogenesis, inhibit cell proliferation or deplete B-cells in an
“individual” according to any of the above embodiments is preferably a human.
In a further aspect, the invention provides for the use of an antibody variant or
polypeptide in the manufacture or preparation of a medicament. In one
embodiment, the medicament is for treatment of cancer or inflammatory diseases.
In a further embodiment, the medicament is for use in a method of treating cancer,
diabetes, neuronal disorders or inflammatory comprising administering to an
individual having cancer, diabetes, neuronal disorders or inflammatory an effective
amount of the medicament. In one such embodiment, the method further comprises
administering to the individual an effective amount of at least one additional
therapeutic agent, e.g., as described below. In a further embodiment, the
medicament is for inhibiting angiogenesis, inhibiting cell proliferation or depleting
B-cells.
In a further embodiment, the medicament is for use in a method of inhibiting
angiogenesis, inhibiting cell proliferation or depleting B-cells
in an individual comprising administering to the individual an amount effective of
the medicament to inhibit angiogenesis, inhibit cell proliferation or deplete B-cells .
An “individual” according to any of the above embodiments may be a human.
In a further aspect, the invention provides pharmaceutical formulations comprising
any of the antibody variants provided herein, e.g., for use in any of the above
therapeutic methods. In one embodiment, a pharmaceutical formulation comprises
any of the antibody variants provided herein and a pharmaceutically acceptable
carrier. In another embodiment, a pharmaceutical formulation comprises any of the
antibody variants provided herein and at least one additional therapeutic agent, e.g.,
as described below.
Antibodies of the invention can be used either alone or in combination with other
agents in a therapy. For instance, an antibody of the invention may be co-
administered with at least one additional therapeutic agent.
Such combination therapies noted above encompass combined administration
(where two or more therapeutic agents are included in the same or separate
formulations), and separate administration, in which case, administration of the
antibody of the invention can occur prior to, simultaneously, and/or following,
administration of the additional therapeutic agent and/or adjuvant. Antibodies of
the invention can also be used in combination with radiation therapy.
An antibody of the invention (and any additional therapeutic agent) can be
administered by any suitable means, including parenteral, intrapulmonary, and
intranasal, and, if desired for local treatment, intralesional administration.
Parenteral infusions include intramuscular, intravenous, intraarterial,
intraperitoneal, or subcutaneous administration. Dosing can be by any suitable
route, e.g. by injections, such as intravenous or subcutaneous injections, depending
in part on whether the administration is brief or chronic. Various dosing schedules
including but not limited to single or multiple administrations over various time-
points, bolus administration, and pulse infusion are contemplated herein.
Antibodies of the invention would be formulated, dosed, and administered in a
fashion consistent with good medical practice. Factors for consideration in this
context include the particular disorder being treated, the particular mammal being
treated, the clinical condition of the individual patient, the cause of the disorder, the
site of delivery of the agent, the method of administration, the scheduling of
administration, and other factors known to medical practitioners. The antibody
need not be, but is optionally formulated with one or more agents currently used to
prevent or treat the disorder in question. The effective amount of such other agents
depends on the amount of antibody present in the formulation, the type of disorder
or treatment, and other factors discussed above. These are generally used in the
same dosages and with administration routes as described herein, or about from 1
to 99% of the dosages described herein, or in any dosage and by any route that is
empirically/clinically determined to be appropriate.
For the prevention or treatment of disease, the appropriate dosage of an antibody of
the invention (when used alone or in combination with one or more other additional
therapeutic agents) will depend on the type of disease to be treated, the type of
antibody, the severity and course of the disease, whether the antibody is
administered for preventive or therapeutic purposes, previous therapy, the patient's
clinical history and response to the antibody, and the discretion of the attending
physician. The antibody is suitably administered to the patient at one time or over a
series of treatments. Depending on the type and severity of the disease, about 1
µg/kg to 15 mg/kg (e.g. 0.1mg/kg-10mg/kg) of antibody can be an initial candidate
dosage for administration to the patient, whether, for example, by one or more
separate administrations, or by continuous infusion. One typical daily dosage might
range from about 1 µg/kg to 100 mg/kg or more, depending on the factors
mentioned above. For repeated administrations over several days or longer,
depending on the condition, the treatment would generally be sustained until a
desired suppression of disease symptoms occurs. One exemplary dosage of the
antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus,
one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any
combination thereof) may be administered to the patient. Such doses may be
administered intermittently, e.g. every week or every three weeks (e.g. such that the
patient receives from about two to about twenty, or e.g. about six doses of the
antibody). An initial higher loading dose, followed by one or more lower doses
may be administered. However, other dosage regimens may be useful. The progress
of this therapy is easily monitored by conventional techniques and assays.
It is understood that any of the above formulations or therapeutic methods may be
carried out using an immunoconjugate of the invention in place of or in addition to
an antibody according to the invention.
Articles of Manufacture
In another aspect of the invention, an article of manufacture containing materials
useful for the treatment, prevention and/or diagnosis of the disorders described
above is provided. The article of manufacture comprises a container and a label or
package insert on or associated with the container. Suitable containers include, for
example, bottles, vials, syringes, IV solution bags, etc. The containers may be
formed from a variety of materials such as glass or plastic. The container holds
a composition which is by itself or combined with another composition effective
for treating, preventing and/or diagnosing the condition and may have a sterile
access port (for example the container may be an intravenous solution bag or a vial
having a stopper pierceable by a hypodermic injection needle). At least one active
agent in the composition is an antibody of the invention. The label or package
insert indicates that the composition is used for treating the condition of choice.
Moreover, the article of manufacture may comprise (a) a first container with a
composition contained therein, wherein the composition comprises an antibody of
the invention; and (b) a second container with a composition contained therein,
wherein the composition comprises a further cytotoxic or otherwise therapeutic
agent. The article of manufacture in this embodiment of the invention may further
comprise a package insert indicating that the compositions can be used to treat a
particular condition. Alternatively, or additionally, the article of manufacture may
further comprise a second (or third) container comprising a pharmaceutically-
acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-
buffered saline, Ringer's solution and dextrose solution. It may further include
other materials desirable from a commercial and user standpoint, including other
buffers, diluents, filters, needles, and syringes.
It is understood that any of the above articles of manufacture may include an
immunoconjugate of the invention in place of or in addition to an antibody variant.
Non-Therapeutic Uses for the Polypeptide
The antibody variant of the invention may be used as an affinity purification agent.
In this process, the antibody variant is immobilized on a solid phase such a
Sephadex resin or filter paper, using methods well known in the art. The
immobilized polypeptide variant is contacted with a sample containing the antigen
to be purified, and thereafter the support is washed with a suitable solvent that will
remove substantially all the material in the sample except the antigen to be purified,
which is bound to the immobilized antibody variant. Finally, the support is washed
with another suitable solvent, such as glycine buffer, pH 5.0, that will release the
antigen from the polypeptide variant.
The antibody variant may also be useful in diagnostic assays, e.g., for detecting
expression of an antigen of interest in specific cells, tissues, or serum.
For diagnostic applications, the antibody variant typically will be labeled with a
detectable moiety. Numerous labels are available which can be generally grouped
into the following categories:
14 125 3 131
(a) Radioisotopes, such as S, C, I, H, and I. The polypeptide variant can
be labeled with the radioisotope using the techniques described in Coligen, et al.,
Current Protocols in Immunology, Volumes 1 and 2, Ed. Wiley-Interscience, New
York, N.Y., Pubs. (1991) for example and radioactivity can be measured using
scintillation counting.
(b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein
and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin
and Texas Red are available. The fluorescent labels can be conjugated to the
polypeptide variant using the techniques disclosed in Current Protocols in
Immunology, supra, for example. Fluorescence can be quantified using a
fluorimeter.
(c) Various enzyme-substrate labels are available and U.S. Pat. No. 4,275,149
provides a review of some of these. The enzyme generally catalyzes a chemical
alteration of the chromogenic substrate that can be measured using various
techniques. For example, the enzyme may catalyze a color change in a substrate,
which can be measured spectrophotometrically. Alternatively, the enzyme may
alter the fluorescence or chemiluminescence of the substrate. Techniques for
quantifying a change in fluorescence are described above. The chemiluminescent
substrate becomes electronically excited by a chemical reaction and may then emit
light which can be measured (using a chemiluminometer, for example) or donates
energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases
(e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin,
2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as
horseradish peroxidase (HRPO), alkaline phosphatase, β-galactosidase,
glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose
oxidase, and glucosephosphate dehydrogenase), heterocyclic oxidases (such as
uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.
Techniques for conjugating enzymes to antibodies are described in O'Sullivan, et
al., Methods for the Preparation of Enzyme-Antibody Conjugates for use in
Enzyme Immunoassay, in Methods in Enzym. (ed J. Langone & H. Van Vunakis),
Academic press, New York, 73:147-166 (1981).
Examples of enzyme-substrate combinations include, for example:
(i) Horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate,
wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene
diamine (OPD) or 3,3′,5,5′-tetramethyl benzidine hydrochloride (TMB));
(ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic
substrate; and
(iii) β-D-galactosidase (β-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl-
β-D-galactosidase) or fluorogenic substrate 4-methylumbelliferyl-β-D-
galactosidase.
Numerous other enzyme-substrate combinations are available to those skilled in the
art. For a general review of these, see U.S. Pat. Nos. 4,275,149 and 4,318,980.
Sometimes, the label is indirectly conjugated with the polypeptide variant. The
skilled artisan will be aware of various techniques for achieving this. For example,
the polypeptide variant can be conjugated with biotin and any of the three broad
categories of labels mentioned above can be conjugated with avidin, or vice versa.
Biotin binds selectively to avidin and thus, the label can be conjugated with the
polypeptide variant in this indirect manner. Alternatively, to achieve indirect
conjugation of the label with the polypeptide variant, the polypeptide variant is
conjugated with a small hapten (e.g., digoxin) and one of the different types of
labels mentioned above is conjugated with an anti-hapten polypeptide variant (e.g.,
anti-digoxin antibody). Thus, indirect conjugation of the label with the polypeptide
variant can be achieved.
In another embodiment of the invention, the antibody variant need not be labeled,
and the presence thereof can be detected using a labeled antibody which binds to
the polypeptide variant.
The antibody variant of the present invention may be employed in any known assay
method, such as competitive binding assays, direct and indirect sandwich assays,
and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of
Techniques, (1987) pp. 147-158, CRC Press, Inc..
The antibody variant may also be used for in vivo diagnostic assays. Generally, the
111 99 14 131 125
polypeptide variant is labeled with a radionuclide (such as In, Tc, C, I, I,
3 32 35
H, P or S) so that the antigen or cells expressing it can be localized using
immunoscintiography. Although the foregoing invention has been described in
some detail by way of illustration and example for purposes of clarity of
understanding, the descriptions and examples should not be construed as limiting
the scope of the invention.
Description of the sequence listing:
SEQ ID NO:1 Human kappa light chain
SEQ ID NO:2 Human lambda light chain
SEQ ID NO:3 Human IgG1 (Caucasian Allotype)
SEQ ID NO:4 Human IgG1 (Afroamerican Allotype
SEQ ID NO:5 Human IgG1 LALA-Mutant (Caucasian Allotype)
SEQ ID NO:6 Human IgG4
SEQ ID NO:7 Human IgG4 SPLE-Mutant which represent exemplary
human sequences for the kappa light chain, lambda light
chain, IgG1 and IgG4 which could serve as basis for
generating the variants according to the invention.
In sequence Id Nos 3-5, the sequence of human IgG1
allotypes, the P329 region according to Kabat EU index is
located at position 212, whereas said P329 region in
sequence Id Nos 6 and 7 can be find at position 209.
SEQ ID NO:8 Kappa light chain of mAb 40A746.2.3
SEQ ID NO:9 Heavy chain of wildtype IgG1 of mAb 40A746.2.3
SEQ ID NO:10 Heavy chain of IgG1 P329G of mAb 40A746.2.3
SEQ ID NO:11 Heavy chain of IgG1 LALA / P329G of mAb 40A746.2.3
SEQ ID NO:12 Heavy chain of IgG4 SPLE of mAb 40A746.2.3
SEQ ID NO:13 Heavy chain of IgG4 SPLE / P329G of mAb 40A746.2.3
SEQ ID NO:14 Heavy chain of IgG1 LALA of mAb 40A746.2.3
Examples
The following seven examples are examples of methods and compositions of the
invention. It is understood that various other embodiments may be practiced, given
the general description provided above.
Although the foregoing invention has been described in some detail by way of
illustration and example for purposes of clarity of understanding, the descriptions
and examples should not be construed as limiting the scope of the invention. The
disclosures of all patent and scientific literature cited herein are expressly
incorporated in their entirety by reference.
Example 1
Antibodies
For the experiments described below antibodies against CD9 (see SEQ IDs 8-14),
P-selectin (sequences described in ) and CD20 (synonym:
GA101, sequences described in EP 1 692 182) were used.
All variants described herein, e.g. P329G, P329A, P329R SPLE, LALA,
P329G/LALA, P329G/SPLE variants of the selectin, CD9, CD20 (GA101) and
CD20 (GA101)-glycoengineered binding antibody (numbering according to EU
nomenclature) were generated using PCR based mutagenesis. IgG molecules were
expressed in the HEK-EBNA or HEK293 (CD9 Fc variants) system, and purified
using protein A and size exclusion chromatography.
Example 2
Determination of the binding affinities of different Fcγ receptors to
immunoglobulins
Binding affinities of different FcγRs towards immunoglobulins were measured by
Surface Plasmon Resonance (SPR) using a Biacore T100 instrument (GE
Healthcare) at 25°C.
The BIAcore® system is well established for the study of molecule interactions. It
allows a continuous real-time monitoring of ligand/analyte bindings and thus the
determination of association rate constants (k ), dissociation rate constants (k ), and
equilibrium constants (K ). Changes in the refractive index indicate mass changes
on the surface caused by the interaction of immobilized ligand with analyte injected
in solution. If molecules bind immobilized ligands on the surface the mass
increases, in case of dissociation the mass decreases.
For a 1:1 interaction no difference in the results should be seen if a binding
molecule is either injected over the surface or immobilized onto a surface.
Therefore different settings were used (with Fcγ receptor as ligand or analyte
respectively), depending on solubility and availability of ligand or corresponding
analyte.
For FcγRI 10000 resonance units (RU) of a capturing system recognizing a
polyhistidine sequence (pentaHis monoclonal antibody, Qiagen Hilden, cat. no.
34660) was immobilized by the use of an amine coupling kit supplied by the GE
Healthcare and a CM5 chip at pH 4.5. FcγRI was captured at a concentration of 5
µg/ml by with a pulse of 60 sec at a flow of 5 µl/min. Different concentrations of
antibodies ranging from 0 to 100 nM were passed with a flow rate of 30 µl/min
through the flow cells at 298 K for 120 sec to record the association phase. The
dissociation phase was monitored for up to 240 sec and triggered by switching
from the sample solution to running buffer. The surface was regenerated by 2 min
washing with a glycine pH 2 solution at a flow rate of 30 ml/min. For all
experiments HBS-P+ buffer supplied by GE Healthcare was chosen (10 mM
HEPES, pH 7.4, 150 mM NaCl, 0.05% (v/v) Surfactant P20). Bulk refractive index
differences were corrected for by subtracting the response obtained from a surface
without captured FcγRI. Blank injections are also subtracted (=double referencing).
The equilibrium dissociation constant (K ), defined as k /k , was determined by
D a d
analyzing the sensogram curves obtained with several different concentrations,
using BIAevaluation software package. The fitting of the data followed a suitable
binding model.
For FcγRIIA and FcγRIIIAV158 10000 resonance units (RU) of a monoclonal
antibody to be tested was immobilized onto a CM5 chip by the use of an amine
coupling kit supplied by the GE (pH 4.5 at a concentration of 10 µg/ml).
Different concentrations of FcγRIIA and IIIA ranging from 0 to 12800 nM were
passed with a flow rate of 5 µl/min through the flow cells at 298 K for 120 sec to
record the association phase. The dissociation phase was monitored for up to 240
sec and triggered by switching from the sample solution to running buffer. The
surface was regenerated by 0,5 min washing with a 3 mM NaOH/1M NaCl solution
at a flow rate of 30 ml/min. For all experiments HBS-P+ buffer supplied by GE
Healthcare was chosen (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% (v/v)
Surfactant P20).
Bulk refractive index differences were corrected for by subtracting the response
obtained from a surface without captured antibody. Blank injections are also
subtracted (=double referencing).
The equilibrium dissociation constant (K ), was determined by analyzing the
sensogram curves obtained with several different concentrations, using BIA
evaluation software package. The fitting of the data followed a suitable binding
model using steady state fitting
For FcγRIIB 10000 resonance units (RU) of a capturing system recognizing a
polyhistidine sequence (pentaHis monoclonal antibody, Qiagen Hilden, cat. no.
34660) was immobilized by the use of an amine coupling kit supplied by the GE
Healthcare and a CM5 chip at pH 4.5. FcγRIIB was captured at a concentration of 5
µg/ml by with a pulse of 120 sec at a flow of 5 µl/min. Different antibodies were
passed at a concentration of 1340 nM with a flow rate of 5 µl/min through the flow
cells at 298 K for 60 sec to record the association phase. The dissociation phase
was monitored for up to 120 sec and triggered by switching from the sample
solution to running buffer. The surface was regenerated by 0,5 min washing with a
glycine pH2.5 solution at a flow rate of 30 ml/min. For all experiments HBS-P+
buffer supplied by GE Healthcare was chosen (10 mM HEPES, pH 7.4, 150 mM
NaCl, 0.05% (v/v) Surfactant P20).
Bulk refractive index differences were corrected for by subtracting the response
obtained from a surface without captured FcγRIIB. Blank injections are also
subtracted (=double referencing).
Due to the very low intrinsic affinity of FcγRIIB to wildtype IgG1 no affinity was
calculated rather a qualitative binding was assessed.
The following tables summarize the effects of introducing a mutation into the Fc
part on binding to FcγRI, FcγRIIA, FcγRIIB, and FcγRIIIAV1-58 (A) as well as the
effect on ADCC (measured without (BLT) and with target cells (ADCC)) and on
C1q binding (B)
Table 2A:
FcγRI FcγRIIaR131 FcγRIIIAV158 FcγRIIB
WT IgG1 ++ (5 nM) ++ (2 µM) + (0,7 µM) ++
IgG4 SPLE - +/- (10µM) - (>20µM) +
IgG1 P329G ++ (6 nM) - (>20µM) - (>20µM) -
IgG1 P329A ge ++ (8 nM) + (4.4 µM) + (1,8 µM) +
IgG1 P329G
LALA - - (>20µM) - (>20µM) -
IgG1 P329G ge ++ (10 nM) - (>20µM) - (>10µM) -
*++ for ge
IgG1
nM
Table 2B:
Mutant FcγRI FcγRII FcγRIII C1q ADCC ADCC
without with
target target
cells cells
Assay Biacore Biacore Biacore CDC C1q BLT ADCC
P329G + -- -- -- -- -- --
P329R n.d. n.d. n.d. n.d. n.d. -- --
LALA - n.d. - - n.d. n.d. --
IgG1_P329G/LALA -- -- -- n.d. n.d. n.d. n.d.
IgG4_SPLE -- - -- -- -- n.d. n.d.
-- strongly reduced/inactive in contrast to wt, - reduced in contrast to wt, +
comparable to wt interaction, n.d. not determined, / no result
In more detail the following results have been obtained:
Affinity to the FcγRI receptor
P329G, P329A, SPLE and LALA mutations have been introduced into the Fc
polypeptide of a P-selectin, CD20 and CD9 antibody, and the binding affinity to
FcγRI was measured with the Biacore system. Whereas the antibody with the
P329G mutation still binds to FcγR1 (Fig. 1a and 1b), introduction of triple
mutations P329G / LALA and P329G / SPLE, respectively, resulted in antibodies
for which nearly no binding could be detected (Fig. 1b). The LALA or SPLE
mutations decreased binding to the receptor more than P329G alone but less than in
combination with P329G (Fig. 1a and 1b). Thus, the combination of P329G with
either LALA or SPLE mutations is much more effective than the P329G mutation
or the double mutations LALA or SPLE alone. The kd value for the CD20 IgG1
wildtype antibody was 4.6 nM and for the P329G mutant of the same antibody 5.7
nM, but for the triple mutant P329G/LALA no kd value could be determined due to
the nearly undetectable binding of the antibody to the FcγRI receptor. The antibody
itself, i.e. whether a CD9 or CD20 or P-selectin was tested, has a minor effect on
the binding affinities.
Affinity to the FcγRIIA receptor
P329G, SPLE and LALA mutations, respectively, have been introduced into the Fc
polypeptide of the CD9 antibody and the binding affinity to the FcγRIIA-R131
receptor was measured with the Biacore system. Binding level is normalized such
as captured mAb represents 100 RU. So not more than approximately 20 RUis
expected for a 1:1 stoichiometry. Fig. 1c shows that the binding to the FcγRIIA
receptor is strongly reduced by introducing the LALA, SPLE/P329G, P329G and
LALA/P329G mutation into the Fc variant. In contrast to binding to the FcγR1
receptor, the introduction of the P329G mutation alone is able to very strongly
block the binding to said receptor, more or less to a similar extent as the triple
mutation P329G / LALA (Fig. 1c).
Affinity to the FcγRIIB receptor
SPLE, LALA, SPLE/P329G and LALA/P329G mutations, respectively, have been
introduced into the Fc polypeptide of the CD9 and P-selectin antibody and the
binding affinity to FcγRIIB receptor was measured with the Biacore system. Fig.
1d shows that the binding to the FcγRIIB receptor is strongly reduced in the LALA
and triple mutants P329G/LALA , P329G / SPLE
Affinity to the FcγRIIIA receptor
P329G,LALA, SPLE, P329G / LALA, and SPLE / P329G mutations have been
introduced into the Fc polypeptide of the CD9 and the binding affinity to
FcγRIIIA-V158 receptor was measured with the Biacore system. The P329G
mutation and the triple mutation P329G / LALA reduced binding to the FcγRIIIA
receptor most strongly, to nearly undetectable levels. The P329G/SPLE also lead to
a strongly reduced binding affinity, the mutations SPLE and LALA, respectively,
only slightly decreased the binding affinity to the FcγRIIIA receptor (Fig. 1e).
Example 3
C1Q ELISA
The binding properties of the different polypeptides comprising Fc variants to C1q
were analyzed by an ELISA sandwich type immunoassay. Each variant is coupled
to a hydrophobic Maxisorp 96 well plate at 8 concentrations between 10 µg/ml and
0 µg/ml. This coupling simulates complexes of antibodies, which is a prerequisite
for high affinity binding of the C1q molecule. After washing, the samples are
incubated to allow C1q binding. After further washing the bound C1q molecule is
detected by a polyclonal rabbit anti-hC1q antibody. Following the next washing
step, an enzyme labelled anti-rabbit-Fcγ specific antibody is added. Immunological
reaction is made visible by addition of a substrate that is converted to a coloured
product by the enzyme. The resulting absorbance, measured photometrically, is
proportional to the amount of C1q bound to the antibody to be investigated. EC
values of the variant- C1q interaction were calculated. The absorption units
resulting from the coloring reaction are plotted against the concentration of the
antibody. The antibody concentration at the half maximum response determines the
EC value. This read-out is reported as relative difference to the reference standard
measured on the same plate together with the coefficient of variation of sample and
reference.
The P329G mutation introduced into the P-selectin or CD20 antibody strongly
reduced binding to C1q, similar to the SPLE mutation (Fig. 2). Table 3 summarizes
the calculated EC 50 values for binding of the variants to the C1q receptor. C1q
belongs to the complement activation proteins and plays a major role in the
activation of the classical pathway of the complement, which leads to the formation
of the membrane attack complex. C1q is also involved in other immunological
processes such as enhancement of phagocytosis, clearance of apoptotic cells or
neutralization of virus. Thus, it can be expected that the mutants shown here to
reduce binding to C1q, e.g. P329G and SPLE, as well as very likely also the triple
mutations comprising the aforementioned single mutations, strongly reduces the
above mentioned functions of C1q.
Table 3:
Antibody EC50 value
P-Selectin IgG1wt 1.8
GA101 IgG1 wt 2.4
P-Selectin IgG1_P329G 2.7
P-Selectin IgG4 SPLE 3.0
GA101 IgG1 P329G 5.5
GA101 IgG4 SPLE >10
Example 4
ADCC without target cells, BLT assay
The antibodies to be tested (CD20 (GA101) and CD9) were coated in PBS over
night at 4°C in suitable 96-flat bottom well plates. After washing the plate with
PBS, the remaining binding sites were blocked with PBS/1 % BSA solution for 1 h
at RT. In the meantime, the effector cells (NK-92 cell line transfected to express
low or high affine human FcγRIII) were harvested and 200 000 living cells/well
were seeded in 100 µl/well AIM V medium into the wells after discarding the
blocking buffer. 100 µl/well saponin buffer (0.5 % saponin + 1 % BSA in PBS)
was used to determine the maximal esterase release by the effector cells. The cells
were incubated for 3 h at 37°C, 5 % CO2 in a incubator. After 3 h, 20 µl/well of the
supernatants were mixed with 180 µl/well BLT substrate (0.2 mM BLT + 0.11 mM
DTNB in 0.1 M Tris-HCL, pH 8.0) and incubated for 30 min at 37°C before
reading the plate at 405 nm in a microplate reader. The percentage of esterase
release was determined setting the maximal release (saponin-treated cells) to 100 %
and the unstimulated cells (no ab coated) to 0 % release.
The wildtype CD20 antibody (GA101 wt (1)) shows strong induction of cytolytic
activity. The LALA variant shows a marked reduction in esterase release, whereas
the P329G and the P329G / LALA variant do not show any ADCC activity (Fig.
3a). Fig. 3b shows that not only an exchange of G at position P329 leads to
markedly reduced cytosolic activity but also an exchange of P329 to R329 (CD20
antibody). Thus arginine appears to destroy the function of the proline sandwich in
the antibody, similar to glycine. The strongly reduced ADCC observed here for the
P329G mutant most likely resulted from the strongly reduced binding to the
FcγRIIA and FcγRIIIA receptor (see Fig. 1c and Fig. 1e).
Example 5
ADCC with target cells
Human peripheral blood mononuclear cells (PBMC) were used as effector cells and
were prepared using Histopaque-1077 (Sigma Diagnostics Inc., St. Louis,
MO63178 USA) and following essentially the manufacturer’s instructions. In brief,
venous blood was taken with heparinized syringes from volunteers. The blood was
diluted 1:0.75-1.3 with PBS (not containing Ca++ or Mg++) and layered on
Histopaque-1077. The gradient was centrifuged at 400 x g for 30 min at room
temperature (RT) without breaks. The interphase containing the PBMC was
collected and washed with PBS (50 ml per cells from two gradients) and harvested
by centrifugation at 300 x g for 10 minutes at RT. After resuspension of the pellet
with PBS, the PBMC were counted and washed a second time by centrifugation at
200 x g for 10 minutes at RT. The cells were then resuspended in the appropriate
medium for the subsequent procedures. The effector to target ratio used for the
ADCC assays was 25:1 and 10:1 for PBMC and NK cells, respectively. The
effector cells were prepared in AIM-V medium at the appropriate concentration in
order to add 50 ml per well of round bottom 96 well plates. Target cells were
human B lymphoma cells (e.g., Raji cells) grown in DMEM containing10% FCS.
Target cells were washed in PBS, counted and resuspended in AIM-V at 0.3
million per ml in order to add 30’000 cells in 100 ml per microwell. Antibodies
were diluted in AIM-V, added in 50 ml to the pre-plated target cells and allowed to
bind to the targets for 10 minutes at RT. Then the effector cells were added and the
plate was incubated for 4 hours at 37˚C in a humified atmosphere containing 5%
CO . Killing of target cells was assessed by measurement of lactate dehydrogenase
(LDH) release from damaged cells using the Cytotoxicity Detection kit (Roche
Diagnostics, Rotkreuz, Switzerland). After the 4-hour incubation the plates were
centrifuged at 800 x g. 100 ml supernatant from each well was transferred to a new
transparent flat bottom 96 well plate. 100 ml color substrate buffer from the kit
were added per well. The V values of the color reaction were determined in an
ELISA reader at 490 nm for at least 10 min using SOFTmax PRO software
(Molecular Devices, Sunnyvale, CA94089, USA). Spontaneous LDH release was
measured from wells containing only target and effector cells but no antibodies.
Maximal release was determined from wells containing only target cells and 1%
Triton X-100. Percentage of specific antibody-mediated killing was calculated as
follows: ((x-SR)/(MR - SR)*100, where x is the mean of Vmax at a specific
antibody concentration, SR is the mean of Vmax of the spontaneous release and
MR is the mean of V of the maximal release.
The potency to recruit immune-effector cells depends on type of Fc variant as
measured by classical ADCC assay. Here, human NK92 cell-line transfected with
human FcgRIIIA was used as effector and CD20 positive Raji cells were used as
target cells. As can be seen in Fig. 4a the ADCC is strongly reduced in GA101
(CD20) Fc variants wherein glycine replaces proline (P329G) and also, to a similar
extent, in the double mutant P329G / LALA. In contrast the ADCC decrease was
less strong with the LALA mutation. In order to better distinguish between the
different variants, the variants were also produced in the glycoengineered version
to enhance the ADCC potential. It can be observed that the parental molecule
(GA101 (CD20)) shows strong ADCC as expected. The LALA version is strongly
impaired in its ADCC potential. The P329G mutant very strongly decreased the
ADCC; much more than a P329A variant of the GA101 (CD20) antibody (Fig. 4b).
Example 6
Complement activity
Target cells were counted, washed with PBS, resuspended in AIM-V (Invitrogen)
at 1 million cells per ml. 50 ml cells were plated per well in a flat bottom 96 well
plate. Antibody dilutions were prepared in AIM-V and added in 50 ml to the cells.
Antibodies were allowed to bind to the cells for 10 minutes at room temperature.
Human serum complement (Quidel) was freshly thawed, diluted 3-fold with AIM-
V and added in 50 ml to the wells. Rabbit complement (Cedarlane Laboratories)
was prepared as described by the manufacturer, diluted 3-fold with AIM-V and
added in 50 ml to the wells. As a control, complement sources were heated for 30
min at 56˚C before addition to the assay. The assay plates were incubated for 2h at
37˚C. Killing of cells was determined by measuring LDH release. Briefly, the
plates were centrifuged at 300 x g for 3 min. 50 ml supernatant per well were
transferred to a new 96 well plate and 50 ml of the assay reagent from the
Cytotoxicity Kit (Roche) were added. A kinetic measurement with the ELISA
reader determined the Vmax corresponding with LDH concentration in the
supernatant. Maximal release was determined by incubating the cells in presence of
1% Triton X-100.
The different Fc variants were analyzed to mediate CDC on SUDH-L4 target cells.
The non-glycoengineered GA101 molecule shows clear induction of CDC. The
LALA variant shows activity only at the highest concentration, whereas and the
P329G and P329G/LALA variants do not show any CDC activity (Fig. 5a).
Moreover, the LALA variant as well as the P329G and P329A variants of a
glycoengineered GA101 molecule do not show any CDC activity (Fig. 5b).
Example 7
Carbohydrate profile of human IgG1
The carbohydrate profiles of human IgG1 antibodies containing mutations within
the Fc, aimed at abrogating the binding to Fcγ receptors, were analyzed by
MALDI/TOF-MS in positive ion mode (neutral oligosaccharides).
Human (h) IgG1 variants were treated with sialidase (QA-Bio) following the
manufacturer’s instructions to remove terminal sialic acid. The neutral
oligosaccharides of hIgG1 were subsequently released by PNGase F (QA-Bio)
digestion as previously described (Ferrara, C. et al., Biotech. Bioeng. 93 (2006)
851-861). The carbohydrate profiles were analyzed by mass spectrometry
(Autoflex, Bruker Daltonics GmbH) in positive ion mode as previously described
(Ferrara, C. et al., Biotech. Bioeng. 93 (2006) 851-861).
The carbohydrate profile of the neutral Fc-associated glycans of human IgG1 is
characterized by three major m/z peaks, which can be assigned to fucosylated
complex oligosaccharide with none (G0), one (G1) or two (G2) terminal galactose
residues.
The carbohydrate profiles of hIgG1 containing mutations within the Fc, aimed at
abrogating binding to Fc receptors, were analyzed and compared to that obtained
for the wild type antibody. The IgG variants containing one of the mutations within
the Fc (P329G, LALA, P329A, P329G/LALA) show similar carbohydrate profiles
to the wild type antibody, with the Fc-associated glycans being fucosylated
complex oligosaccharides (data not shown). Mutation within the Fc can affect the
level of terminal galactosylation and terminal sialylation, as observed by replacing
amino acid at positions 241, 243, 263, 265, or 301 by alanine (Lund, J. et al., J.
Immunol. 157 (1996) 4963–4969).
Figure 6a shows the relative percentage of galactosylation for the different hIgG1
Fc-variants described here. Slight variations can be observed when the antibodies
are expressed in a different host, but no significant difference in terminal
galactosylation could be observed.
Figure 6b indicates the variability in galactosylation content for wild type and
IgG1-P329G / LALA for 4 different antibodies, where four different V-domains
were compared for their amount of galactosylation when expressed in Hek293
EBNA cells.
Example 8
Antibody–induced platelet aggregation in whole blood assay.
Whole blood platelet aggregation analysis using the Multiplate instrument from
Dynabyte. First, 20 ml blood from normal human donors are withdrawn and
transferred into hiruidin tubes (Dynabyte Medical, # MP0601). Plug minicell
impedance device (Dynabead #MP0021) into the Multiplate instrument was used
for the assay. Then, 175 µl 0.9 % NaCl were added to the minicell. Antibody was
added to minicell to obtain the final test concentration. Then, 175 µl human blood
were added and incubated for 3 min at 37°C. Automated start of impedance
analysis for additional 6 min at 37°C. The data were analyzed by quantification of
area-under-the-curve as a measure of platelet aggregation.
The CD9 antibody has been shown to induce platelet activation and platelet
aggregation (Worthington, et al., Br. J. Hematol. 74(2) (1990) 216-222). Platelet
aggregation induced by antibodies binding to platelets previously has been shown
to involve binding to FcγRIIA (de Reys, et al., Blood 81 (1993) 1792-1800). As
shown above the mutations LALA, P329G, P329G/LALA and P329G/SPLE
introduced into the CD9 antibody strongly reduced binding of the CD9 antibody to
the FcγRIIA receptor (Fig. 1c).
The activation (measured by Ca efflux, data not shown) as well as platelet
aggregation induced by a CD9 antibody was eliminated by introducing the P329G
and LALA triple mutation into the antibody such that the FcγRIIA binding is
strongly reduced compared to the wildtype antibody (see Fig. 7a and 7b). Murine
IgG1 induced platelet aggregation at low antibody concentrations (0.1-1 µ/ml). At
higher concentrations overstimulation of platelets leads to silencing of the
aggregation response (3-30 µg/ml). Donor variability was observed with chim-hu-
IgG4-SPLE. In Fig. 6a data for a chim-hu-IgG4-SPLE responder at higher antibody
concentrations and in Fig. 6b data for a chim-hu-IgG4-SPLE non-responder is
shown. None of the blood samples showed any aggregation response with the
antibody variants chim-hu-IgG1-LALA, chim-hu-IgG-WT-P329G, chim-hu-IgG1-
LALA-P329G, chim-hu-IgG4-SPLE-P329G, chim-hu-IgG4-SPLE-N297Q.
Controls: spontaneous aggregation in untreated blood sample (background); ADP-
induced (ADP) and Thrombin analogon-induced (TRAP6) platelet aggregation.
Isotype controls: Murine IgG1 (murine Isotype) and human IgG4-SPLE (hu-IgG4-
SPLE Isotype).
One possible interpretation of these data is that the decreased binding of the CD9
antibody with the triple mutations to the FcγRIIA receptor is the reason for the
diminished platelet aggregation observed with these kind of mutant antibodies. In
principle, prevention of thrombocyte aggregation, as a toxic side-effect of an
antibody treatment, might thus be possible by introducing the above mentioned
mutations, capable of reducing binding to the FcγRIIA receptor, into the Fc part of
an antibody.
Patent
Claims (12)
1. A polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising an amino acid substitution at position Pro329, wherein Pro329 of a wild-type human Fc region is substituted with glycine or 5 arginine, and wherein the Fc variant comprises at least two further amino acid substitutions, wherein said further amino acid substitutions are L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region, wherein the residues are numbered according to the EU index of Kabat, and wherein said polypeptide exhibits an at least 10-fold 10 reduced affinity to the human FcγRIIIA and a reduced affinity to the human, FcγRIIA, FcγRI and the human C1q receptor, compared to a polypeptide comprising the wildtype IgG Fc region, and wherein the ADCC induced by said polypeptide is reduced to 0-20% of the ADCC induced by the polypeptide comprising a wild-type human IgG Fc region. 15
2. The polypeptide according to claim 1, wherein the polypeptide comprises a human IgG1 or IgG4 Fc region.
3. The polypeptide according to claim 1 or 2, wherein the polypeptide is an antibody or an Fc fusion protein.
4. The polypeptide according to any one of claims 1-3, wherein thrombocyte 20 aggregation induced by the polypeptide is reduced compared to the thrombocyte aggregation induced by a polypeptide comprising a wild-type human IgG Fc region.
5. The polypeptide according to any one of claims 1-4, wherein CDC induced by the polypeptide is strongly reduced compared to the CDC induced by a 25 polypeptide comprising a wild-type human IgG Fc region.
6. The polypeptide according to any one of claims 1-5 for use as a medicament.
7. The polypeptide according to any one of claims 1-6, wherein the polypeptide is an anti-CD9 antibody, which is characterized in that the polypeptide comprising the wildtype Fc region comprises as heavy chain variable region 30 SEQ ID NO:9 and as variable light chain region SEQ ID NO:8.
8. The polypeptide according to any one of claims 1-7, for use in treating a disease wherein it is favorable that an effector function of the polypeptide is strongly reduced compared to the effector function induced by a polypeptide comprising a wild-type human IgG Fc region. 5
9. Use of the polypeptide according to any one of claims 1-8 in the manufacture of a medicament for the treatment of a disease, wherein it is favorable that the effector function of the polypeptide comprising an Fc variant of a wild-type human IgG Fc region is strongly reduced compared to the effector function induced by a polypeptide comprising a wild-type human IgG Fc region.
10 10. Use of a polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said polypeptide having Pro329 of the human IgG Fc region substituted with glycine, and wherein the Fc variant comprises at least two further amino acid substitutions, wherein said further amino acid substitutions are L234A and L235A of the human IgG1 Fc region or S228P 15 and L235E of the human IgG4 Fc region, wherein the residues are numbered according to the EU index of Kabat, wherein said polypeptide exhibits a reduced affinity to the human FcγRIIIA and FcγRIIA, in the manufacture of a medicament for down-modulation of ADCC to 0-20% of the ADCC induced by the polypeptide comprising the wildtype human IgG Fc region, and/or for 20 down-modulation of ADCP.
11. The use according to claim 10, wherein thrombocyte aggregation induced by the polypeptide is reduced compared to the thrombocyte aggregation induced by a polypeptide comprising a wildtype human Fc region, wherein the polypeptide is a platelet activating antibody. 25
12. A polypeptide according to any one of claims 1-8 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11160251 | 2011-03-29 | ||
EP11160251.2 | 2011-03-29 | ||
PCT/EP2012/055393 WO2012130831A1 (en) | 2011-03-29 | 2012-03-27 | Antibody fc variants |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614658A NZ614658A (en) | 2015-07-31 |
NZ614658B2 true NZ614658B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210139603A1 (en) | Antibody fc variants | |
EP3215532B1 (en) | Anti-tim3 antibodies and methods of use | |
US9732148B2 (en) | Anti-α-synuclein antibodies and methods of use | |
US20220275076A1 (en) | Anti-myostatin antibodies and methods of use | |
KR20190049771A (en) | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use | |
WO2021006328A1 (en) | Claudin-6 binding molecules and uses thereof | |
KR20150023938A (en) | Anti-theophylline antibodies and methods of use | |
NZ614658B2 (en) | Antibody fc variants | |
TW201245227A (en) | Antibody Fc variants |